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Abstract	  
 
Prostate cancer is a very important health problem in the UK and worldwide. 
Available treatments such as radiotherapy, surgery and androgen ablation have 
failed to significantly increase the life expectancy of prostate cancer patients. 
Therefore researching new treatments is paramount. A promising approach for 
prostate cancer is suicide gene therapy. In this work, the use of the 
NTR/CB1954 enzyme/prodrug system delivered by a baculovirus vector was 
investigated for its application in prostate cancer cell lines and prostate primary 
epithelial cultures. The results suggest that the NTR/CB1954 system is highly 
efficient in causing cell death in prostate cell lines and prostate primary 
epithelial cultures. The use of a baculovirus vector to deliver the NTR gene 
resulted in increased transduction of prostate cancer cell lines in comparison to 
non-malignant prostate and non-prostate cell lines. To target NTR expression to 
prostate cells the regulation of the hTGP promoter was dissected. hTGP 
expression was confirmed to be highly prostate specific and mainly regulated by 
retinoic acid, androgens, retinoic acid receptor gamma and the androgen 
receptor. This work presents the first evidence of an interaction between these 
nuclear receptors and challenges the current model for prostate specific 
expression. Finally a baculovirus encoding the NTR gene under the control of 
the hTGP promoter was tested in prostate cancer cell lines resulting in 
moderate cell death. These findings are very encouraging but in order to use 
the hTGP promoter for gene therapy there needs to be further manipulation of 
the sequence to optimise its potency while maintaining its prostate specificity 
The use of NTR and baculovirus coupled to the targeting controlled provided by 
the hTGP promoter could develop into a potent and specific approach to treat 
prostate cancer. 
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1.	  INTRODUCTION	  
 
1.1 Prostate anatomy and physiology  
The human prostate is a small glandular organ located close to the base of the 
bladder and surrounding the urethra. The main function of this gland is the 
production of fluids that are part of the semen composition (Vo and Goodman 
2001). 
The prostate can be divided into four anatomical zones; the central is the 
second largest zone, forms the majority of the prostate’s base and surrounds 
the ejaculatory ducts. The peripheral is the largest of the zones; it surrounds 
the central zone and a portion of the urethra. The transition zone surrounds 
the proximal urethra and grows throughout the lifespan of men. Finally there is 
the anterior zone, which is devoid of glandular activity and composed of 
muscular and fibrous tissue (figure 1). 
 
	  
Figure 1 Human prostate anatomy, sagittal view (Kundra et al. 2007). 
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The prostate is a highly organised organ. The epithelial compartment is formed 
by a cellular bilayer with phenotypically distinct cells (figure 2). The luminal 
stratum is the more abundant cellular phenotype in prostatic epithelium; it is 
comprised of terminally differentiated cells that produce high amounts of 
secreted proteins such as the prostate specific antigen and prostatic acid 
phosphatase. Luminal cells are characterized by their high expression of 
androgen receptor (AR) and cytokeratins 8 and 18 (Brawer et al. 1985; 
Sherwood et al. 1990; Bonkhoff and Remberger 1993). Basal cells are less 
differentiated in comparison to luminal cells; they do not produce secreted 
products and are not directly dependent on androgens as luminal cells are and 
therefore express very low levels of AR (De Marzo et al. 1998). Basal cells 
express CD44, cytokeratin 5, cytokeratin 14 and p63, a p53-homologue 
important in prostate for cell lineage commitment and development (Signoretti 
et al. 2005; Grisanzio and Signoretti 2008). Neuroendocrine cells, a scarce third 
phenotype in the prostate epithelium, are differentiated cells that are androgen 
independent and express various neuropeptides such as chromogranin A and 
serotonin. Neuroendocrine cells are thought to provide signals to support the 
growth of luminal cells (Abrahamsson et al. 1998; Bonkhoff 1998; di 
Sant'Agnese 1998).  
Further analysis of the prostate epithelium has uncovered an additional degree 
of complexity. The discovery of cells with intermediate characteristics between 
luminal and basal phenotypes has prompted the proposition of a hierarchy 
model that constantly renews the prostate epithelium. The discovery of a 
subpopulation of basal cells with a high proliferation rate that expresses both 
basal and luminal-associated cytokeratins (Hudson et al. 2001; Lang et al. 
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2001), the isolation of prostate epithelial stem cells (Richardson et al. 2004) and 
prostate stem cell lineage tracking using lentiviruses encoding fluorescent 
protein genes under the control of promoters active in late stages of 
differentiation (Frame et al. 2010), support the hierarchical model for the 
prostate epithelium. 
 
 
 
	  
Figure 2. Human prostate epithelium, modified from (Oldridge et al. 2011) 
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1.1.1 Prostate development 
The prostate gland develops from the urogenital sinus (UGS), which has an 
endodermal origin (Prins and Putz 2008). Prostate development commences 
with the commitment of UGS cells to prostatic cell fate. This is followed by the 
formation of UGS epithelial buds that penetrate into the surrounding UGS 
mesenchyme (Prins and Putz 2008). Branching morphogenesis of the prostate 
buds, which occurs when the elongating UGS epithelial buds contact the 
prostate mesenchyme, is co-ordinated with epithelial and mesenchymal 
differentiation (Prins and Birch 1995). Epithelial cells differentiate into basal and 
luminal cells. This differentiation is characterized by fluctuating patterns of 
cytokeratin and AR expression. Mesenchymal cells differentiate into periductal 
smooth muscle and fibroblasts (Hayward et al. 1996). 
 
1.1.2 Regulation of prostate development by hormones 
The onset of prostate development is mainly dependent on the presence of 
androgens (Cunha 1973). Despite the androgen requirement for prostate 
development, constant presence of these hormones is not needed to trigger 
differentiation. The study carried out by Cunha showed that UGM explants from 
male mice grown in the absence of androgen produced budded structures if the 
UGM explants were obtained after the mice started to produce testosterone. 
This means that androgen trigger an irreversible commitment that continues in 
the absence of this hormone (Cunha 1973). Interestingly, AR needs to be 
expressed in the UGS mesenchyme but not in the UGS epithelia, to promote 
prostatic morphogenesis. This was demonstrated through tissue recombinant 
studies. Grafted AR-deficient murine UGS epithelium combined with wild-type 
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murine UGS mesenchyme resulted in androgen dependent ductal 
morphogenesis. In a complementary study, wild-type murine UGS epithelium 
combined with AR-deficient murine UGS mesenchyme grafts resulted in 
vaginal-like differentiation (Cunha and Chung 1981; Cunha et al. 1987). 
Despite the major role of androgens in prostate biology, other hormones can 
regulate prostate development. Oestrogen exposure during early development 
can modify prostate development by altering the expression of genes such as 
NKX3.1 and HOX13, which are closely involved in prostate development (Prins 
et al. 2001; Huang et al. 2004). Retinoic acid (RA) also plays an important role 
in prostate development. Retinoic acid, mainly through the retinoic acid 
receptors (RARs), controls the proliferation and differentiation of prostate 
epithelium (Peehl et al. 1993; Seo et al. 1997). Underlying the importance of 
this hormone in prostate development is the description of prostate squamous 
metaplasia in mice lacking RARG expression, which render the mice completely 
sterile (Lohnes et al. 1995). 
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1.2 Steroid receptors in the prostate 
1.2.1 Androgen receptor 
The AR is a nuclear receptor and transcription factor and it is a member of the 
steroid and nuclear receptor superfamily (Montgomery et al. 2001; Heinlein and 
Chang 2002). In the absence of ligand the AR is present in the cytoplasm of 
cells, interacting with heat shock proteins (HSPs) and cytoskeletal proteins that 
allow efficient ligand binding (Veldscholte et al. 1992; He et al. 1999; He et al. 
2000; Cardozo et al. 2003). After ligand binding the AR undergoes 
conformational changes that affect its interaction with other proteins and DNA 
(Liao et al. 2003). One of the key results of these conformational changes is AR 
detachment from HSPs. This facilitates AR interaction with proteins such as 
ARA70, Filamin-A and importin-α, which bind to the nuclear localisation signal 
(NLS), enabling nuclear shuttling and dimerisation (Rahman et al. 2004; 
Schaufele et al. 2005; Cutress et al. 2008). 
Once in the nucleus, active AR binds to consensus DNA sequences named 
androgen responsive elements (AREs). AR binding to AREs triggers the 
recruitment of histone acetyltransferase (HAT) enzymes, co-regulators and 
transcription machinery that activates transcription from target genes (figure 3) 
(Heinlein and Chang 2002; Powell et al. 2004). 
The AR regulates genes involved in a variety of biological processes. Genes 
that encode prostate secreted products such as PSA, kallikrein 2 and prostatic 
acid phosphatase have been characterised as androgen regulated (Nelson et al. 
1998). Genes related to cell survival are also androgen regulated. Androgens 
decrease the levels of p53 in a time and dose dependent manner (Rokhlin et al. 
2005). In the rat ventral prostate the same effect is observed probably induced 
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by the increased expression of the negative p53 regulator Mdm2 and down 
regulation of the positive p53 regulators Hoxa5 and Egr1 (Nantermet et al. 
2004). Interestingly, the apoptotic regulator caspase-2 has been shown to be 
regulated by the AR in prostate cells. Upon androgen treatment, capase-2 
expression decreases in a dose-dependent manner. The AR directed regulation 
of the caspase-2 gene was confirmed by demonstrating AR binding to an ARE 
located in the intron 8 of this gene (Rokhlin et al. 2005). 
Cell cycle-related proteins are also regulated by the AR. The cyclin-dependent 
kinase inhibitor p21, induced after androgen stimulation, has been described as 
a direct AR target (Lu et al. 1999). In a recent study, it was found that genes 
such as E2F1, CDC25, CDK6, CDC14 and CDC2, all related to cell cycle 
progression and regulation, were up regulated following androgen treatment 
(Massie et al. 2011). In the same report it was noted that genes related to 
glucose, lipid, nucleotide and amino-acid metabolism are also positively 
regulated after androgen treatment, which emphasises the importance of the 
AR as a key regulator of prostate biology. 
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Figure 3. Androgen receptor signalling pathway. Testosterone is transformed to DHT by the 
enzyme 5α-reductase (1). DHT binds to the AR promoting its dissociation from HSPs chaperone 
complexes and allowing it to interact with importin-α and ARA70 which stabilises the receptor (2 
and 3) and promote translocation to the nucleus (4). Once in the cell’s nucleus AR dimerises (5) 
and binds to AREs in target genes promoting transcription by recruiting co-activators such as 
P/CAF and CBP/p300 (6). Non-ligand-bound AR is then shuttled back to the cytoplasm in 
preparation for more ligand binding (7) or degraded by the proteasome (8). Taken from (Bennett 
et al. 2010) 
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1.2.2 Retinoic acid receptors 
The RARs, like the AR, belong to the superfamily of nuclear receptors. There 
are three different isotypes, RARα, RARβ and RARγ, encoded by three different 
genes (Chambon 1996). The role of the RARs is emphasised by the effects of 
vitamin A deficiency (VAD) syndrome both during development (congenital 
malformation affecting ocular cardiac, respiratory and urogenital systems) and 
after birth (growth retardation, widespread squamous metaplasia of glandular 
and transitional epithelia and degeneration of testis, retina and motoneurons) 
(Wilson et al. 1953; Chambon 1996; Morriss-Kay and Ward 1999; Mark et al. 
2006). Vitamin A is the precursor of RA, which is the main ligand that triggers 
the RARs activity. In the absence of ligand, the RARs are found in the nucleus. 
They form heterodimers with the retinoid X receptors and are bound to specific 
sequences in the DNA termed retinoic acid responsive elements or RAREs, 
composed of direct repeats of a core hexameric motif (Leid et al. 1992; 
Mangelsdorf and Evans 1995). When RA binds to the RARs it causes the 
dissociation of co-repressors such as NCoR, SMRT and HDACs, from the RAR-
RXR complex due to protein conformational changes (Egea et al. 2001). These 
changes in protein structure uncover surfaces for the interaction of the RAR-
RXR complex with co-activators including the SRC/p160 family and p300/CBP 
(Glass and Rosenfeld 2000; McKenna and O'Malley 2002). The main role of 
these co-activators is the relaxation of the surrounding chromatin through 
histone modifications (Rosenfeld et al. 2006) which allows the posterior 
recruitment of the transcription machinery to the promoter (Dilworth and 
Chambon 2001; Woychik and Hampsey 2002) that in turn activates gene 
transcription (figure 4). 
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The RARs, being the main RA receptors, participate in a variety of biological 
processes, which are essential for the development and homeostasis of many 
organs and systems. The RARs can control the expression of HOX genes, thus 
have a direct role in the early development of many organs and systems 
including heart, urogenital system, eyes, pancreas and lungs (Duester 2008). 
Apoptosis is another important process regulated by RARs. Caspase 7 and 9 
are up-regulated by RA. Caspase 9 is a direct target of RARs due to the 
presence of a functional RARE in its second intron (Donato and Noy 2005), 
which explains the increase in apoptosis following RA treatment. Also, RARB 
has been shown to regulate HOXA5, a potent inducer of cell death in breast 
cells, through a RARE site located at the 3’ end of the gene. Down-regulation of 
RARB abolishes the apoptotic effects of RA treatment due to low expression of 
HOXA5 (Chen et al. 2007). Differentiation is another key process regulated by 
RARs. RARs increase the expression of proteins that modify chromatin, 
transcription factors and signalling effectors that enhance differentiation (Gudas 
and Wagner 2011). RARs are known to be involved in bone (Karakida et al. 
2011), neuron (Ito et al. 2011), prostate (Peehl et al. 1993), liver (Huang et al. 
2009) and stem cell (Purton et al. 2006; Chatzi et al. 2010) differentiation 
among other cell types and tissues. 
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Figure 4. Retinoic acid-mediated gene expression. A. In the absence of ligand the RAR/RXR 
heterodimers are bound to the DNA and interact with co-repressors such as HDAC and NCoR 
to actively repress transcription. B. Following ligand binding, the RAR/RXR dimers undergo a 
conformational change that triggers interaction with co-activators such as PCAF, p300/CBP and 
other proteins with HAT activity to promote chromatin remodelling. C. Once the chromatin is in 
an open state, ligand bound RAR/RXR recruits the transcription machinery including TBP, the 
TFs, the mediator complex and RNA pol II to the transcription start site to begin transcription. 
Figure taken from (Bastien and Rochette-Egly 2004). 
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1.3 Prostate cancer  
Prostate cancer is a predominant health problem in the UK, as one in every four 
new cases of diagnosed cancer in men is prostate cancer.  This disease has an 
age-related component, with the majority of prostate cancer cases detected in 
men aged over 60 years (Cancer Res UK Prostate Cancer 2010). Despite the 
role of aging in prostate cancer there are incidence differences between 
populations that suggest prostate cancer is more than a by-product of age.  
 
1.3.1 Risk factors for prostate cancer 
-Inflammation 
Inflammation seems to be connected to the onset of prostate cancer. 
Administration of PhIP (2-amino-1methyl-6phenyl-imidazo[4,5-b]pyridine), a 
potent inductor of inflammation, in rodents results in prostate hyperplasia and 
prostate intraepithelial neoplasia (PIN) which represents a precursor lesion to 
prostate cancer (Borowsky et al. 2006). Interestingly, regions of focal atrophic 
epithelium in the prostate can be associated with an inflammatory process. 
These regions, termed proliferative inflammatory atrophy or PIA, display 
increased proliferation and are often adjacent to PIN and adenocarcinoma (De 
Marzo et al. 1999). Possible causes for inflammation in the prostate could 
include physical trauma, bacterial or viral infection, altered hormone levels or 
diet (De Marzo et al. 2007). It has been shown that induced bacterial prostatitis 
in mice results in lesions resembling PIA and down regulation of Nkx3.1 
expression, a key tumour suppressor gene often down regulated in prostate 
cancer (Khalili et al. 2010). These findings are supported by the known 
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susceptibility of the prostate gland to infections and the identification of multiple 
bacteria in prostatectomy samples (Sfanos et al. 2008). 
 
-Oxidative stress and DNA damage 
One of the major factors contributing to prostate cancer might be oxidative 
stress and subsequent DNA damage. Damage to DNA can occur when reactive 
oxygen species (ROS) accumulate inside cells and the detoxifying enzymes fail 
to cope with the challenge (Minelli et al. 2009). The prostate seems to be 
especially vulnerable to oxidative stress with inflammation, hormonal 
deregulation and diet as the main factors contributing to the accumulation of 
ROS. The observation that enzymes involved in ROS detoxification have low 
expression in pre-malignant lesions and prostate cancer, and the role of the 
tumour suppressor gene Nkx3.1 in regulating the expression of genes that 
respond to oxidative damage implies a role for oxidative stress in the 
development of malignancies (Bostwick et al. 2000; Ouyang et al. 2005). 
 
-Genomic alterations 
Genomic analysis of prostate cancer has revealed diverse chromosomal 
alterations and rearrangements associated with carcinogenesis. Gains at 8q 
and losses at 3p, 8p, 10q, 13q and 17p are examples of well-documented 
chromosomal alterations (Lapointe et al. 2007; Taylor et al. 2010). The 
identification of some of these changes in PIN and PIA lesions suggest the 
possibility that these genomic changes contribute to the carcinogenesis process. 
The mechanisms by which these lesions could induce cancer include copy 
number alterations of genes like NKX3.1, PTEN and MYC. How deregulation of 
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these genes leads to prostate cancer will be discussed further in following 
sections. 
 
-Loss of senescence 
Senescence is a cell cycle arrest in which cells remain viable but do not 
proliferate even when challenged with mitogen signals (d'Adda di Fagagna 
2008). Senescence has been proposed to act as a mechanism of tumour 
suppression following oncogenic insults. Senescence has been shown as a 
frequent process in benign prostate hyperplasia (BPH) (Choi et al. 2000), with 
p14arf and p16ink4a, genes associated  with senescence, increasing with aging, 
particularly in non-malignant tumours (Zhang et al. 2006). In genetically 
engineered mice that lack Pten expression, PIN lesions arise with a senescent 
phenotype. Loss of senescent phenotype is achieved by inactivating p53 and 
Skp2, which suggests that senescence could be a barrier that prevents 
transformed cells from progressing to advanced disease stages (Chen et al. 
2005; Narita et al. 2010). 
 
1.3.2 Genes involved in prostate cancer 
-PTEN 
Phosphatase and tensin homologue (PTEN) is a 403 amino-acid protein 
localized in the plasma membrane and nucleus of the cells. Its main function is 
to down-regulate the intracellular levels of phosphatidylinositol-(3,4,5)-
triphosphate (PIP3) (Maehama and Dixon 1998), which is a major product of 
the PI3K enzyme. PIP3 promotes phosphorylation of Akt by recruiting it to the 
cell membrane and activating phosphoinositide dependent kinases (PDKs) 
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(Kandel and Hay 1999). Phosphorylated Akt plays an important role in cell 
survival, promoting phosphorylation and inactivation of Bad and caspase 9, 
active components of the cell’s death machinery (Datta et al. 1997 and Cardone 
et al. 1998). The importance of PTEN in prostate cancer development is 
underlined by the fact that PTEN is localized in the 10q23 region which is often 
deleted in prostate cancer (Wang et al. 1998b). PTEN inactivation is sustained 
in different prostate cancer cell lines and xenografts. In PC3 cells homozygous 
deletion of PTEN was detected, while in LNCaP cells the exon1 bears a frame-
shift mutation that prevents PTEN translation (Vlietstra et al. 1998). 
PTEN has also been associated with the onset of castration-resistant prostate 
cancer. Loss or reduction of PTEN expression paves the way for castration-
resistance as demonstrated in mouse models where conditional PTEN deletion 
stimulates prostate cancer metastasis and androgen-independent proliferation 
(Wang et al. 2003). 
 
-NKX3.1 
NKX3.1 gene encodes a transcription factor homeodomain protein that is 
essential for prostate function and morphogenesis (Bhatia-Gaur et al. 1999). It 
belongs to the NK subfamily of homebox genes and is highly expressed in the 
prostate. This important gene is located in a chromosomal region, 8p21, where 
loss of heterozygosity often occurs in PIN lesions and prostate cancer tumours 
(Asatiani et al. 2005). Lack of alterations in the remaining allele raise the 
possibility of NKX3.1 haploinsufficiency as a mechanism to abolish NKX3.1 
activity (Abdulkadir et al. 2002). Around 50% of PIN lesions and primary 
prostate tumours and as high as 80% of metastatic tumours show decreased 
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NKX3.1 expression, suggesting a possible role for NKX3.1 in prostate 
carcinogenesis and tumour aggressiveness (Bowen et al. 2000). One of the 
proposed mechanisms by which NKX3.1 protects prostate cells is its role in 
DNA damage response. Inactivation of this gene in mice results in a poor 
response to oxidative damage, while NKX3.1 expression in human prostate 
cancer cell lines protects against DNA damage (Ouyang et al. 2005; Bowen and 
Gelmann 2010). NKX3.1 has also been shown to suppress tumour growth in 
mice and cell proliferation and androgen independent growth in vitro (Kim et al. 
2002).  
 
-MYC 
Several studies have demonstrated that MYC mRNA levels are up-regulated in 
PIN lesions and prostate cancer in comparison to BPH and normal tissue 
(Fleming et al. 1986; Buttyan et al. 1987). While MYC overexpression at the 
mRNA level seems consistent, MYC protein levels and localisation in prostate 
cancer is still unclear. Presence of MYC in the cytoplasm of cancer cells has 
been reported (Jenkins et al. 1997; Yang et al. 2005). However, MYC presence 
was localised in the nuclei of the cells, with little difference between benign and 
cancer samples (Fox et al. 1993). A more recent article describing the use of a 
rabbit monoclonal antibody against MYC, validated for immunocytochemistry, 
shows a strong nuclear localisation and a higher expression in malignant versus 
benign samples (Gurel et al. 2008). 
A chromosomal region commonly amplified in advanced and recurrent prostate 
cancer is 8q24.21. This region contains the gene MYC, and its amplification is 
thought to be related to the high mRNA and protein expression found in 
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prostate cancer (Gurel et al. 2008). While gain of the chromosome 8 is relatively 
frequent, MYC locus amplification appears to be less common (Nupponen et al. 
1998), and when it does occur is in the order of a few-fold increase, a modest 
up-regulation when compared to expression of NMYC in other cancers such as 
neuroblastoma. Evidence so far shows a poor correlation between 8q24 
amplification and MYC expression, mostly because 8q24 gain is infrequent in 
PIN lesions, while MYC in the same lesions is higher than in benign tissues 
(Gurel et al. 2008). MYC overexpression promotes prostate cancer 
development through differential regulation of genes and proteins. Nkx3.1 
expression is low in high MYC expressing cells (Ellwood-Yen et al. 2003), while 
hTERT expression is increased (Wang et al. 1998a) and EZH2 is up-regulated 
by MYC due to down-regulation of mir26a that represses EZH2 expression (Koh 
et al. 2010), 
While current evidence suggests a role for MYC in prostate cancer, more 
studies are necessary to consolidate current evidence and provide a 
mechanism by which MYC promotes the development of prostate cancer. 
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1.4 AR and castration-resistant prostate cancer 
The role of AR in prostate homeostasis has been discussed previously, 
however it also plays a major role in prostate cancer. Survival of prostate tissue 
is closely linked to androgen (figure 5A). Androgen deprivation causes high 
rates of apoptosis in prostate cells that interact with the stromal component 
(figure 5B), but not in those cultured without stroma where androgen depletion 
only causes low rates of proliferation (Gao et al. 2006). The importance of AR 
for prostate cells survival and its role in the development of prostate cancer 
resulted in the treatment of this disease by means of limiting the concentration 
of androgens available to the tumour. Although tumour shrinkage and prostate 
cancer biomarker PSA levels decrease after androgen deprivation, almost 
invariably, prostate cancer relapses with an acquired resistance to 
castration/castration-like treatments (Feldman and Feldman 2001). Castration-
resistant prostate cancer (CRPC) retains AR expression, suggesting that this 
receptor is still playing an important role (Han et al. 2005). Experiments with 
xenografts, selected by their castration-resistance, show that these cells have a 
higher AR expression (figure 5C) and that treatment of these cells with AR 
antagonists had an agonist effect, stimulating AR activity (Chen et al. 2004). 
Other mechanisms to retain AR activity include gain-of-function mutations that 
increase protein stability, a broader response to other steroid hormones, 
increased sensitivity to androgens (figure 5D) and ligand independent activity 
(figure 5E) (Zhao et al. 2000; Robzyk et al. 2007; Steinkamp et al. 2009). 
Despite the assumption that AR performs the same activities in CRPC, a new 
study suggests that actually, AR activity in CRPC cells activates a different 
pathway to promote growth and survival. In CRPC, in contrast to castration-
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sensitive prostate cancer, the AR up-regulates M-phase cell-cycle genes 
including UBE2C, a gene that disables the M-phase checkpoint (Wang et al. 
2009). 
Whether castration-resistant prostate cancer is an inevitable development of 
prostate cancer is still debatable. There are currently two main hypotheses to 
explain the onset of CRPC. The adaptation model proposes that androgen 
deprivation forces androgen-dependent cells to adapt in order to survive the 
new conditions. The clonal selection model suggests that the proliferation of 
CRPC cells is the result of the expansion of a rare set of previously quiescent 
cells that were castration-resistant preceding androgen deprivation (Isaacs and 
Coffey 1981). 
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Figure 5. Castration-resistance molecular mechanisms. A. Normal response to androgen in 
epithelial cells: high concentrations of androgen trigger AR activity. B. Low androgen 
concentrations stimulate pro-apoptotic signal production by the stroma component to induce cell 
death in the epithelium. C. AR amplification results in AR activity in a low androgen environment 
and overcomes the pro-apoptotic signals coming from the stroma. D. AR mutations can stabilise 
the AR, promoting its activity in a low androgen environment. E. Activation of other signalling 
pathways can induce AR activity and oppose the pro-apoptotic signals caused by the low 
androgen concentration. Modified from (Shen and Abate-Shen 2010). 
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1.5 Prostate cancer stem cells 
There are currently two main models that attempt to explain the cellular origin of 
prostate cancer and other solid tumours. The first hypothesis, known as the 
stochastic model, proposes that within the prostate tumour the majority of the 
cells possess high tumorigenic potential. Tumour heterogeneity develops from 
the expansion of clones with growth/resistance advantages and are decisive for 
the evolution of the tumour (Shackleton et al. 2009). An alternative model 
proposes the existence of cancer stem cells (CSC) to explain the heterogeneity 
found in prostate tumours and acquired resistance to treatments, particularly to 
androgen withdrawal (figure 6). According to this model, CSC accumulate 
mutations and alterations during their extended lifespan, that result in the 
generation of malignant progeny following an aberrant differentiation program 
(Rosen and Jordan 2009). Some of the proposed characteristics of prostate 
CSC are androgen independence, due to lack of expression of AR, indefinite 
self-renewal potential, asymmetric division and a high rate of tumour initiation 
ability.  
Several observations support the CSC theory; one of the most interesting being 
that androgen deprivation causes regression and apoptosis in prostatic 
epithelium, but once androgens are restored, the prostate undergoes full 
recovery both structurally and functionally (English et al. 1987; Evans and 
Chandler 1987). This implies that within the prostate epithelium there must be a 
subset of cells with the ability to give rise to the prostate hierarchy that are 
castration resistant. A similar observation occurs when a prostate cancer patient 
undergoes chemical castration treatment. The tumour shrinks and PSA levels 
decrease during the early stages of the treatment. Unfortunately, in almost all 
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cases the tumour relapses and becomes castration-resistant and further 
treatments are limited to palliative actions (Denmeade and Isaacs 2002). This 
suggests the presence of cells with stem-like properties in prostate cancer 
tumours that are resistant to castration and generate a progeny with the same 
characteristics. Moreover, the same cell surface markers used to identify 
prostate epithelial stem cells (Richardson et al. 2004) can be used to isolate 
cells with increased clonogenicity, proliferation and self-renewal from prostate 
cancer biopsies (Collins et al. 2005), suggesting that normal epithelial prostate 
stem cells are the cell of origin for prostate cancer. 
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Figure 6. Stochastic and cancer stem cell mechanisms that could lead to prostate cancer 
development. The stochastic mechanism proposes that luminal cells suffer a loss of growth 
control and cell:cell interactions that when combined with a cell life-span increase, produces 
dedifferentiated cancer cells. The cancer stem cell mechanism proposes that normal stem cells 
suffer mutations that activate malignancy and that these cancers stem cells follow an aberrant 
differentiation program. Figure adapted from (Maitland et al. 2011) 
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1.6 Current treatments for prostate cancer. 
Current treatments available for prostate cancer are often offered to patients 
depending on the stage of the disease. Gleason grade (Gleason 1966) and 
PSA score (Placer and Morote 2011) are the most used tools in prostate cancer 
diagnosis. Gleason grade scores prostate cancer using 5 grades depending on 
the differentiation status of the tissue and although it was established in 1966 it 
remains the most useful prognostic tool for prostate cancer. PSA levels are 
correlated to the presence of prostate cancer. The higher the PSA levels the 
more likely to detect prostate cancer, however this test is not 100% reliable and 
cannot distinguish between aggressive and non-aggressive cancers. 
 
1.6.1 Radical prostatectomy 
 Radical prostatectomy is the most successful treatment for localized prostate 
cancer when compared to other treatments (Bill-Axelson et al. 2005). This 
approach is intended to completely remove all the cancerous tissue that is 
confined within the prostatic capsule and therefore could be curative. There are 
two main downsides to this approach; first, for this treatment to be effective, the 
cancer needs to be detected at a very early stage without clear signs of 
spreading outside the prostate, something that even with the current screening 
methods is still very unlikely. Secondly, there are a number of possible side 
effects such as sexual dysfunction and urinary incontinence (Catalona et al. 
1999).  
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1.6.2 Radiotherapy 
Another treatment for organ-confined prostate cancer is radiation therapy. It 
consists of the use of ionizing radiation over a portion of tissue to control its 
growth through DNA damage and the cascade response generated by it. 
Radiation therapy for prostate cancer has two variants; external beam 
radiotherapy or brachytherapy (Duchesne 2011). 
External beam radiotherapy refers to the use of an external source of ionising 
radiation targeting a particular part of the body where the tumour is localised, in 
this case, the prostate. Brachytherapy is the internal use of radioactive seeds 
located next to the tumour. While the principle of both treatments is the same, 
there are certain differences between both approaches. Whereas external 
beam radiation therapy is less invasive, brachytherapy reduces the amount of 
healthy tissue that is irradiated and therefore some of the undesired side-effects 
caused by radiation (Jani and Hellman 2003). 
 
1.6.3 Androgen deprivation therapy 
Another treatment that can be used as a monotherapy or in combination with 
surgery or radiotherapy is androgen deprivation therapy. This treatment is often 
used to treat advanced or metastatic prostate cancer, and relies on the luminal 
cells’ dependence on androgens for survival. Since cells with a luminal 
phenotype comprise the majority of the prostate tumour, androgen deprivation 
results in a rapid decrease in tumour size. However, in time, the majority of the 
tumours treated with androgen deprivation therapy relapse, becoming more 
aggressive and insensitive to androgen deprivation therapy and other common 
treatments (Yagoda and Petrylak 1993; Rashid and Chaudhary 2004). Other 
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well-documented side effects that prevent the wider use of androgen 
deprivation therapy are osteoporosis, skeletal complications, arterial stiffness, 
cognitive decline and fatigue (Isbarn et al. 2009). 
 
1.6.4 Chemotherapy 
Chemotherapy is often considered the last line of defence against CRPC. 
Commonly used drugs include docetaxel, paclitaxel and vinblastine. These 
drugs target dividing cells by inhibiting the mitotic spindle assembly therefore 
preventing cells from completing mitosis (Yvon et al. 1999). However, CRPC 
can become resistant to these agents by decreasing proliferation rates and 
increasing resistance to apoptosis (Berges et al. 1995). Combination of 
chemotherapeutic agents and androgen deprivation therapies prolong the mean 
time life expectancy in a range of months only (Seruga and Tannock 2011). 
 
Current treatments against prostate cancer have failed to take into account the 
heterogeneous nature of prostate cancer. Their outcome is the selection of 
prostate cancer cells which are resistant to these therapies, making the cancer 
more aggressive. Therefore, new therapies specifically designed to consider the 
many characteristics of prostate cancer are needed to provide a successful 
treatment with the ultimate outcome of improving patient’s life expectancy and 
quality. 
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1.7 Gene therapy as an alternative treatment for prostate cancer 
Gene therapy is by definition the transplantation of normal genes into cells in 
place of missing or defective ones in order to correct inherited genetic disorders. 
However, the term gene therapy has also been applied to the delivery of 
therapeutic genes to treat a given non-genetic disease. The main aim of gene 
therapy is the successful delivery of therapeutic genetic material to a specific 
tissue or cell (El-Aneed 2004). To achieve this goal, two types of vectors 
capable of delivering genetic material can be used, viral and non-viral vectors. 
Among the most studied non-viral vectors we find cationic lipids (Felgner et al. 
1994), cationic polymers such as polyethylenimines (Breunig et al. 2005) and 
poly (L-lysine) (Ward et al. 2001). These non-viral vectors are considered safer 
vehicles for gene transfer, since they are not modified pathogens and do not 
trigger a host immune response, but their ability to transduce cells in vivo and in 
vitro is significantly lower when compared to the efficiency of viral vectors 
(Breunig et al. 2005). Conversely, viral-vectors, with the advantage of a more 
efficient gene delivery, need to be engineered to suppress their unregulated 
reproduction, immunogenicity and need to be used in limiting doses due to their 
potential toxic effect. At present, several viruses have been selected as 
promising vectors for gene delivery but in order to understand the advantages 
and disadvantages in the use of these viruses, a basic knowledge of their 
biology is necessary. 
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1.7.1 Viral vectors for gene therapy 
1.7.1.1 Adenovirus 
Human adenoviruses are non-enveloped icosahedral particles with a double 
stranded DNA genome. The adenoviral capsid contains minor and major capsid 
proteins,  encoded in the adenovirus late genes. Hexon proteins are the major 
component of the adenoviral capsid. They possess a β-barrel structural motif 
found in the icosahedral capsids of many DNA viruses. At the capsid vertices a 
penton capsomere, a covalent complex of two proteins, attaches to a fiber 
protein containing a globular knob domain in the distal tip. While hexon proteins 
play a major role in the structure of the capsid itself, pentons and fibers are 
involved in virus-cell interactions and viral tropism (Glasgow et al. 2006). 
 
-Adenovirus Infection 
The virus entry to the cell is mediated by the coxsackie/adenovirus receptor 
(CAR), which interacts with the globular knob domain in the fiber protein. This 
interaction results in a clathrin-mediated endocytosis of viral particles. As the 
viral particles travel through the endosome pathway within the cell cytoplasm, 
the virus-encoded proteases release the core components from the capsid; 
these components are then directed to the nucleus passing through the nuclear 
pore to initiate transcription of viral genes. The first genes to be transcribed are 
termed E1, E2, E3 and E4 (E stands for early transcribed gene). These genes 
change the cell regulation, inhibit apoptosis, shut down the cell protein 
synthesis, provide viral replication machinery, and facilitate the process of viral 
particle exit from the host cell. The DNA replication starts from both termini of 
the viral genome, and from then on, late transcription events initiate. There are 
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five late transcripts named L1, L2, L3, L4 and L5; the products of these 
transcripts are the structural components of the virus. The presence of these 
components leads to virus assembly, maturation and eventual viral egress from 
the cell (Russell 2000). 
 
-Adenovirus Relevant Features for Gene Therapy 
Adenovirus can infect dividing and non-diving cells (Quantin et al. 1992), which 
is a very valuable attribute when trying to target differentiated or slow growing 
cells. They can also be modified in order to prevent uncontrolled replication and 
potential oncogenicity and to increase their transgene carrying capacity. 
Deletion of the E1 gene region causes the virus to become replication-deficient 
and dependent on a helper cell line for viral propagation; by deleting the E3 
gene the carrying capacity can be augmented, because E3 is a non-essential 
replication region, even though its presence is desirable in oncolytic 
adenoviruses, give its capacity to modulate the immune response (Sharma and 
Andersson 2009). The need for larger cloning capacity has led to the creation of 
high capacity or “gutless” vectors containing only inverted terminal repeats and 
packaging signals (for replication and packaging of viral DNA) and therefore 
they can enclose inserts up to 37 kb (Young et al. 2006). 
 
1.7.1.2 Retrovirus 
Retroviruses are wide-spread among the animal kingdom. Most retroviral virions 
are spherical particles of around 80-100 nm in diameter. They are encircled by 
a lipid bilayer derived from the host cell plasma membrane and contain viral 
envelope proteins. Inside the envelope is the viral capsid, mainly comprised of 
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the product of the viral gag gene. The retrovirus’ genome consists of two copies 
of an RNA molecule along with a tRNA primer for reverse transcription and 
small amounts of reverse transcriptase protein. Complex retroviruses encode 
several other proteins involved in viral replication or cell response to the virus 
(Anson 2004). 
 
-Retrovirus Infection 
The first step of retroviral infection is the interaction of viral particles with the cell 
surface. There is not enough data to conclude if this first interaction occurs 
through specific molecules, but it is likely that the implicated proteins are 
dissimilar from the viral receptor responsible for the entry process. After this first 
interaction, viral particles use cell surface proteins as specific receptors. In 
order to gain access into the host cell the viral envelope proteins interact with 
these cell surface proteins. This interaction leads to a fusion between both 
cellular and viral membranes, and releases the viral core into the cytoplasm. 
Once the viral core is released, two processes are triggered: the reverse 
transcription of the viral RNA genome and a partial and progressive 
disassembly or uncoating of the viral particle. Subsequently, the viral DNA 
needs to reach the nucleus and it is likely that the cytoskeleton is being used to 
gain access to this cellular organelle. As part of their life cycle, retroviruses 
need to integrate the reverse transcribed DNA into the host genome. A good 
number of retroviruses are incapable of accessing the intact nuclei and must 
wait for nuclear breakdown during mitosis (even though, some retrovirus can 
replicate in non-dividing cells which might mean that they are capable of 
entering an intact nucleus). Once in the nucleus the integration process is 
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directed by the viral protein integrase. The position in the cell genome where 
integration occurs seems to be chromatin-status and viral-type dependent. After 
integration, the provirus is transcribed as another normal cell gene, which leads 
to the generation of viral proteins and viral RNA genome. These transcripts are 
transported to the cytoplasm where translation of viral capsid proteins occurs; 
subsequently viral particles are assembled and coated by the cell plasma 
membrane (which already has the viral envelope proteins) when budding out of 
the cell (Nisole and Saib 2004). 
 
-Retrovirus Relevant Features for Gene Therapy 
The retrovirus life cycle includes an integration step into the host genome and 
stable transmission to daughter cells, an important characteristic when trying to 
achieve long-term transgene expression. As the virus itself encodes all the 
genes needed for viral replication, it is easy to remove all viral genes and 
maintain only long terminal repeats required for RNA genome packaging. 
Retrovirus vectors were initially based on Moloney murine leukaemia virus 
(MoMuLV) that is incapable of crossing the nuclear membrane, and therefore 
can only infect dividing cells. This distinctive attribute is convenient because 
cancer cells are in constant proliferation, hence the retrovirus vector can only 
infect the dividing cancer cells and is harmless to the healthy tissue. 
Unfortunately, a tumor consists of dividing and non-dividing cells, which would 
result in partial infection and poor therapeutic impact. This problem stimulated 
the interest in lentivirus vectors, that can infect dividing and non-dividing cells 
with high efficiency. Lentiviruses are engineered in the same way as 
retroviruses, deleting all virulence genes and using helper cell lines for 
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replication and packaging. Still, random insertion into the DNA genome and the 
activation of cellular oncogenes are problems that require further research 
(Young et al. 2006). 
 
1.7.1.3 Herpes Simplex Virus 
Herpes Simplex Virus (HSV) is a double-stranded DNA virus with a lipid 
envelope that is embedded with glycoproteins responsible for receptor-ligand 
interactions. Between the envelope and the capsid there is a protein layer 
called tegument that has functions related to host protein synthesis down-
regulation, viral gene induction and virion assembly. Finally, the 
icosadeltahedral capsid contains 152 kb of dsDNA (Burton et al. 2001). 
 
-Herpes Simplex Virus Infection 
The entry of HSV into host cells initiates with the attachment of HSV 
glycoproteins to heparan sulphate molecules in the cell surface. This binding 
promotes the virus union with the viral entry receptor, which can be heparan 
sulfate, herpes virus entry mediator (HVEM) or members of the nectin family. 
The recognition of the entry receptor results in the fusion between the viral 
envelope and the cell membrane, releasing the nucleocapsid into the cytoplasm. 
The nucleocapsid is then transported to the nucleus by the cytoskeleton.  If the 
virus follows the lytic pathway, a regulated sequential expression of genes 
termed immediate early (IE), early (E) and late (L) initiate. The expression of the 
IE genes relies on the protein VP16, a tegument component, that in association 
with cellular factors activates their transcription. The successful IE gene 
expression leads to transcription of the E genes, which then change the 
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intracellular environment to favour viral replication. The structural proteins 
encoded by the L genes are produced after the replication of the viral genome; 
the assembly of viral particles always leads to cell death. If the DNA enters a 
latent state, then it persists as an episomal element with almost no 
transcriptional activity (Lachmann 2004). 
 
-HSV Relevant Features for Gene Therapy 
HSV based vectors have a large transgene cloning capacity as almost half of 
their 152 kb genome is dispensable for replication purposes.  In the same way 
as most viral vectors, HSV vectors contain gene deletions to abolish viral gene 
expression or enclose several conditional mutations that suppress viral gene 
expression, because the expression of even a few viral genes could lead to 
cytotoxicity. HSV vectors have a useful quality, in that they can persist in a 
latent state when they reach sensory neurons. This is a way to achieve long-
term expression, but since a large part of the population has already been in 
contact with wild-type replicative efficient HSV, and as the infection is latent, the 
probability of recombination and thus cytotoxic effects is larger than desired 
(Lachmann 2004). 
 
1.7.1.4 Adeno-Associated Virus 
Adeno-Associated virus (AAV) belongs to the family Parvoviridae, genus 
Dependovirus, because productive infection can only occur in the presence of a 
helper virus. AAV are small (22-25 nm) non-enveloped viruses with linear 
single-stranded DNA contained in an icosahedral capsid. It is the only 
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mammalian DNA virus known to be capable of integrating at a relatively specific 
site of the human genome (Daya and Berns 2008). 
 
-AAV Infection 
AAV first attaches to heparan sulfate proteoglycans, and the binding to αVβ5 
integrin heterodimers, fibroblast growth factor receptor type 1 and the 
hepatocyte growth factor receptor c-Met triggers the internalization process. 
The virus pathway leading to the nucleus has not been clearly identified, but it 
seems that this pathway initiates with receptor-mediated endocytosis and then 
liberation to the cytoplasm due to a pH dependent process (Bartlett et al. 2000). 
It is not clear if the virus accesses the nucleus through the nuclear pore 
complex, but the pathway that follows (nuclear pore-dependent or independent) 
is likely to depend on the presence of a helper virus. Once the virus is in the 
nucleus it starts expressing regulatory proteins that, depending on the presence 
of a helper virus, up- or down-regulates DNA replication. When viral replication 
is promoted, viral proteins interact with cellular factors and promote DNA 
synthesis, transcription and translation of structural genes, which then lead to 
virion assembly, and the egress of viral particles out of the cell. If there is no 
helper virus inside the cell, then the AAV genome integrates into the human 
chromosome 19 (a region designated as AAVS1), still being able to initiate a 
productive infection when a helper virus infects the cell (Goncalves 2005). 
 
-AAV Relevant Features for Gene Therapy 
The apparent non-pathogenic nature of AAV and its capability of site directed 
integration make this virus a good candidate for gene therapy purposes. The 
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most common way of generating recombinant AAV particles is transfecting cells 
with a plasmid containing the gene of interest flanked by AAV inverted terminal 
repeats (ITRs) and with another construct containing the viral rep and cap 
genes (for replication and capsid formation, respectively). In the presence of Ad 
helper functions (either by infection or by transfection) the gene of interest is 
rescued from the plasmid backbone and packaged into AAV capsids 
(Goncalves 2005).  Despite the multiple advantages of the AAV system, the 
lack of large cloning capacity is a significant weakness. 
 
1.7.1.5 Baculovirus 
The Baculovirus family comprises a wide range of invertebrate and insect 
viruses. The most used species for gene therapy purposes is the Autographa 
californica nucleopolyhedrovirus or AcMNPV. Its genome is comprised of 
double-stranded and covalently closed circular DNA. AcMNPV have rod-shaped 
capsids which are covered by an envelope containing peplomers made of gp64 
protein. AcMNPV can also be found in structures named occlusion bodies. 
These are formed in the nucleus and are enveloped nucleocapsids embedded 
in a protein matrix (O´Reilly DR 1992). Since in this work AcMNPV was the only 
baculovirus species used, hereafter will refer to AcMNPV as baculovirus for 
ease of reference. 
 
-Baculovirus Infection 
Infection in cell culture comprises three basic phases: early, late and very late. 
In the early phase, the viral particles gain entry into the cell through interaction 
with the cell membrane and adsorptive endocytosis. The nucleocapsid is then 
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transported to the nucleus, following interaction with the nuclear pore complex. 
After reaching the nucleus, viral RNA is rapidly transcribed and the cells 
undergo several changes, including cytoskeleton and chromatin 
rearrangements to support the viral cycle. In the late phase, DNA replication, 
late gene expression and baculovirus production all take place. In the very late 
phase the nucleocapsids are enveloped in the nucleus and covered by a 
polyhedrin protein matrix. It is important to note that baculovirus is incapable of 
productively infecting mammalian cells, even though its DNA can be found in 
the nuclei of these cells (O´Reilly DR 1992).  
 
-Baculovirus Relevant Features for Gene Therapy 
Baculoviruses have been largely studied as vectors for expression of human 
proteins in an insect cell-based system. The advantages of the baculovirus 
protein expression system are correct protein folding, diverse post-translational 
modifications and high safety when using these viral agents, as they are 
considered non-pathogenic to humans. In the 1980s it was found that 
baculovirus DNA can reach the nucleus of mammalian cells without any sign of 
transcription of viral DNA (Tjia et al. 1983). The list of permissive cells to 
baculovirus transduction has expanded; it comprises not only a broad number 
of human cell lines (table 1), but also other vertebrate cell lines. It has become 
evident that the molecule responsible for viral attachment and entry to 
mammalian cells is the viral protein gp64. After attachment, the virus enters the 
cell via endocytosis and follows the endosomal pathway, escaping to the 
cytoplasm (a process dependent on gp64) and then being transported to the 
nucleus using the cytoskeleton (Stanbridge et al. 2003; Hu 2006) (figure 7). The 
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facts that baculovirus can transduce a mammalian cell without expressing most 
viral genes, that most humans have not been in contact with the virus and 
hence do not show previous immunity against it, and the highly scalable nature 
of baculovirus production, make this vector a very interesting and promising 
option for human gene therapy.  
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Cell type Reference 
HeLa (Condreay et al. 1999) 
Huh-7 (Condreay et al. 1999) 
HepG2 (Boyce and Bucher 1996) 
HEK293 (Sollerbrant et al. 2001) 
WI38 (Condreay et al. 1999) 
MRC5 (Palombo et al. 1998) 
MG63 (Condreay et al. 1999) 
ECV-304 (Airenne et al. 2000) 
HUVEC (Kronschnabl et al. 2002) 
PC3 (Stanbridge et al. 2003) 
KATO-III (Shoji et al. 1997) 
SAOS-2 (Condreay et al. 1999) 
Pancreatic β cells (Ma et al. 2000) 
Keratinocytes (Condreay et al. 1999) 
Bone marrow fibroblast (Condreay et al. 1999) 
Primary foreskin fibroblast (Dwarakanath et al. 2001) 
Primary neural cells (Sarkis et al. 2000) 
Primary hepatocytes (Boyce and Bucher 1996) 
Mesenchymal stem cells (Ho et al. 2005) 
 
Table 1. Human cell types permissive to baculovirus transduction. Table adapted from (Hu 
2006). 
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Figure 7. Baculovirus infection of insect cells (left) and transduction of mammalian cells (right). 
In insects there are two forms of infection, the first one occurs when occluded virus (OV) is 
released by the alkaline environment of the midgut and taken into the cell’s cytoplasm, where 
the protein matrix is degraded, liberating the viral core. The second one occurs when a progeny 
baculovirus (BuV) enters in contact with an insect cell through the gp64 proteins on the 
membrane of the virus, which triggers endocytosis and membranes fusion between the viral 
membrane and the endosome, releasing the viral core into the cytoplasm. In both cases, the 
viral core is taken to the nucleus where virus replication begins. In mammalian cells the 
baculovirus gains entry into the cell using the gp64 protein present in its envelope. The 
baculovirus core is released into the cytoplasm and then taken into the cell’s nucleus where the 
transgene can be expressed from a mammalian promoter. Figure adapted from (Stanbridge et 
al. 2003). 
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1.8 Gene Therapy Strategies for Prostate Cancer 
The persistent study of prostate cancer biology has led to the development of 
potential gene therapeutic strategies that, depending on its foundation, aim for 
apoptosis, suicide therapy, immune system activation, oncolysis and correction 
of defective genes. All these strategies take advantage of the cancer cell’s 
molecular modifications, which allow it to proliferate at a great rate, evade the 
immune system, and change to an aberrant expression pattern. 
 
1.8.1 Corrective Gene therapy 
This strategy attempts to use tumour suppressor genes to restore the proper 
regulation of the cell cycle or use antisense sequences to down-regulate an 
oncogene that contributes to the abnormal cell cycle in prostate cancer. An 
important therapeutic gene used for this purpose is the tumour suppressor gene 
p16; due to the finding that p16 inactivation is common in an elevated number 
of prostate cancer cases. Experiments expressing the p16 gene in several 
prostate cancer cell lines have shown growth inhibition and/or senescence, 
depending on the genetic background of the cell line (Steiner et al. 2000). 
Another suitable candidate is the tumour suppressor gene p53, as abnormal 
p53 function is commonly associated with an advanced stage and metastasis in 
prostate cancer. Adenovirus containing p53 gene have been used to treat 
prostate cancer in a mouse model with good results (Eastham et al. 1995). The 
over expression of the myc oncogene in prostate cancer has prompted the use 
of antisense mRNA to decrease the protein levels of myc, a strategy that is able 
to suppress and in some cases eradicate human tumours growing in nude mice 
(Lu 2001).  In a similar way the transduction of pro-apoptotic genes to cancer 
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cells (caspase-7 and Bax) have a positive effect on the tumour mass reduction 
(Mazhar and Waxman 2004). As these methodologies require almost 100% of 
transduction efficiency, it is more likely that they are used as a paired approach 
rather than as single therapies. 
 
1.8.3 Oncolytic Gene Therapy 
Oncolytic gene therapy refers to the use of cancer, tumour or tissue-selective 
replication competent viruses to kill malignant cells. These viruses show an 
increased ability to replicate in cancer/tissue-specific cells in comparison to non-
malignant/unspecific cells. Conditional replication in cancer cells can be 
achieved by the use of cancer related or tissue specific promoters regulating 
the expression of key viral replication genes. One of the most used regulatory 
regions to control adenovirus replication is the hTERT promoter. In these 
replication-competent viruses, hTERT has been used to control the expression 
of E1A, therefore limiting viral replication to hTERT expressing cells (Onimaru et 
al. 2010; Doloff et al. 2011). Another exploitable approach is to use tissue 
specific approaches to regulate viral replication. The ARR2PB promoter has 
been used to restrict the replication of the HSV virus to prostate cells, resulting 
in enhanced tumour specificity and lysis (Lee et al. 2010).This therapy has the 
advantage of needing relatively low amounts of virus to induce a therapeutic 
effect, since the therapeutic particles amplify within the cancer cells. However, 
the host immune response is still a challenge to be addressed by the oncolytic 
approach, since circulating antibodies and Cytotoxic T-cell response limit the 
therapeutic effect of these viruses (Davis and Fang 2005). 
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1.8.4 Suicide Gene Therapy 
This approach is also known as gene-dependent enzyme prodrug therapy 
(GDEPT), and consists of the introduction of a metabolizing enzyme into target 
cells followed by the addition of a prodrug in a systemic way. The enzyme then 
will transform the non-toxic prodrug into a cytotoxic form, which in turn will kill 
the enzyme expressing cells (figure 8). The advantage of this approach is that 
high transduction efficiency is not required because of the so called “bystander 
effect”, which is thought to occur by the toxic agent diffusing to neighboring cells. 
The most used systems for GDEPT are the HSV gene for thymidine kinase in 
combination with the gancyclovir prodrug and the cytosine deaminase with the 
5-fluorocytosine prodrug (MacRae et al. 2006). 
 
Thymidine kinase is an enzyme encoded by the herpes simplex virus 1 (HSV-1) 
and it participates in the reactivation of the viral life cycle after a period of 
latency. This enzyme can be used to phosphorylate the prodrug gancyclovir 
(GCV), which is the rate limiting step in the conversion of GCV to its cytotoxic 
form (Portsmouth et al. 2007). Following phosphorylation by viral thymidine 
kinase the monophosphorylated GCV is then transformed to a triphosphate 
form by cellular enzymes. This compound is capable of inhibiting cellular DNA 
polymerases, and it can be incorporated into nascent DNA molecules leading to 
single-strand breaks and cellular death by means of apoptotic and non-
apoptotic pathways depending on the cell model (Portsmouth et al. 2007). The 
main disadvantage when using HSVtk/GCV is that the active prodrug is unable 
to diffuse to neighbouring cells and the bystander effect has less impact on cell 
killing.  
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Cytosine deaminase is another enzyme used for suicide gene therapy. A 
specific feature is that the gene is only found in bacteria and fungi, but not in 
humans. Yeast cytosine deaminase is the preferred type because of its higher 
processive ability effect for the prodrug 5-fluorocytosine (5-FC), which then is 
converted to 5-fluorouracil (5-FU), a chemotherapeutic agent used to treat 
carcinomas in humans.  5-FU can then be converted into other compounds that 
interfere with the activity of the thymidylate synthase and can be incorporated 
into RNA and DNA, interfering with nuclear processing of rRNA and mRNA and 
causing DNA damage. These effects are augmented by the bystander effect of 
the active prodrug, that occurs without the need for cell-cell contact or facilitated 
diffusion (Portsmouth et al. 2007). These effects lead to cell growth inhibition 
and apoptosis-mediated cell death in a variety of cancers including prostate 
cancer (Freytag et al. 2003).  
 
Nitroreductase enzyme is another suitable candidate for GDEPT, as it can 
process the CB1954 prodrug from a low cytotoxicity compound to a fully 
functional alkylating agent that causes extensive DNA cross-linking (Searle et al. 
2004). It has been shown in a mouse fibroblast cell line that the 
nitroreductase/CB1954 system is functional even when only 10% of the cells 
were expressing nitroreductase. In the same study, transgenic mice expressing 
nitroreductase in T cells but not in other tissues showed a decrease in T cell 
population after CB1954 treatment, while other tissues studied remained 
unaffected (Drabek et al. 1997). The principal advantages of the 
nitroreductase/CB1954 system is the low transduction efficiency required for 
cell killing; CB1954 does not display cross-resistance with any cytotoxic agent 
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currently in use, and is effective under hypoxic conditions (Portsmouth et al. 
2007). Moreover, a mutant bearing an amino acid change, has proved to be 
more efficient at activating CB1954 (Grove et al. 2003), and recently a 
nitroreductase double-mutant has been generated with a higher specificity for 
CB1954 than for other substrates (Race et al. 2007). The use of the 
NTR/CB1954 prodrug system could be particularly successful in prostate 
cancer given the low proliferation rate and heterogeneity of the disease and the 
ability of the activated prodrug to kill both proliferating and non-proliferating cells 
(Jaberipour et al. 2010). 
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Figure 8. Suicide gene therapy or GDEPT. This approach relies on an enzyme encoding or 
suicide gene in combination with a non-cytotoxic prodrug. When the gene is delivered, target 
cells begin to produce the activating enzyme. Following prodrug  treatment the enzyme 
transforms the prodrug into a potent cytotoxic agent that accumulates in the cell leading to 
apoptosis/cell death. 
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1.9 Targeting Viral Tropism 
Another strategy that can be used to direct the expression of therapeutic genes 
is to change or modulate viral tropism. Viruses have a natural “preference” for 
certain molecules on the cell surface that allows them to gain entry into the cell. 
In some cases, this natural tropism might be desirable, but in most cases an 
attenuation of natural viral tropism is desirable.  
 
1.9.1 Pseudotyping 
Pseudotyping is “changing the tropism of a virus by replacing the viral 
attachment protein with that of a related virus” (Waehler et al. 2007) (figure 9A). 
Among the vectors that can be subject to pseudotyping are adenovirus, AAV, 
retrovirus and lentivirus. A common technique is to co-transfect plasmids, one 
with the coding sequence of the desired attachment protein and another with 
the rest of the necessary elements to give rise to a functional viral vector 
(Waehler et al. 2007). Pseudotyping has been performed in enveloped 
(Schnierle et al. 1997) and non-enveloped viruses (Mercier et al. 2004). It is 
more difficult to achieve good results in substituting proteins in non-enveloped 
viruses due to the high similarity needed between the native and the 
pseudotyping molecule, in order to preserve the capsid structure and 
functionality which can be easily disrupted. 
 
1.9.2 Adaptor Proteins 
Another approach is to use adaptor proteins to link the target molecule in the 
cell and the viral attachment protein in the virus surface (figure 9B). This can be 
achieved using receptor-ligand complexes, where the viral receptor is 
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genetically fused to the ligand of a receptor expressed in the target cell or tissue 
(Waehler et al. 2007). A further method, called chemical conjugation, covalently 
links the targeting ligand to the vector using Polyethylene glycol (PEG) 
(Waehler et al. 2007). 
 
1.9.3 Genetic Incorporation 
A more promising method is genetic incorporation (figure 9C). This approach 
aims to fuse a recognition sequence in the capsid or surface proteins of virions 
in a way that it can mediate the attachment of the viral particle to the target cell. 
The expression of a single-chain antibody on the viral surface has been tested 
in adenovirus, AAV, retrovirus and herpes simplex virus (Menotti et al. 2006; 
Waehler et al. 2007), showing good results.  Moreover, as the introduction of 
large peptides to the viral structure may lead to incorrect folding and affect the 
way the virion is assembled, a less risky approach is the use of small peptide 
motifs. These are less likely to affect the tertiary structure of the protein, where 
they might be inserted, and yet they can keep high specificity (Waehler et al. 
2007). 
 
Despite the high potential for changing the natural tropism of viral vectors, this 
methodology is not being exploited in the prostate cancer area. One of the few 
published studies of this approach uses a viral vector resulting from the 
combination of an M13 derived filamentous phage and AAV. The resultant 
chimeric vector, which displays an RGD-4C peptide, is able to bind the αV 
integrins that are regularly over-expressed in tumour and endothelial cells. This 
chimeric vector was first tested in cell cultures showing high specificity for αV 
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integrin-positive cells. The chimeric vector was also tested in a mouse model of 
human prostate cancer, and showed high transgene expression in the prostate. 
Even when the liver showed non-specific clearance of the phage, there were no 
signs of infection in that organ (Hajitou et al. 2006).  
Figure 9. Different approaches for virus re-targeting. A. Pesudotyping consists of substituting a 
native virus envelope protein for that of a different strain or virus. B. Adaptor proteins facilitate 
integration of the viral attachment protein and the cell receptor on the surface of the virus. This 
technique also enables targeting of specific cell receptors, using specific antibodies bound to 
the virus through an IgG binding domain. C. Genetic incorporation is a term often used to 
describe genetic modifications to viral proteins in order to add a new binding domain. This can 
be obtained by fusing the viral protein to a single chain antibody or by including a motif for a 
different receptor. 
 
 
 
 
 
 
A B C 
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1.9.4 Transcriptional targeting 
If gene therapy strategies for cancer were used systematically, without aiming 
to target cancer cells, undesired expression of potentially toxic genes would be 
likely to occur in healthy tissue. This problem may be overcome by 
transcriptional targeting. This approach intends to limit the expression of 
therapeutic genes to a specific tissue or cell population, taking advantage of the 
distinctive cellular transcription factors in each tissue or by exploiting the over 
expression of some of these in cancer cells. Thus, using a promoter that can be 
activated only by a certain transcription factor(s), can limit the expression of the 
desired gene(s) to a tissue or cell population. Many promoters have been used 
to target the expression of therapeutic genes. These promoters can be 
classified as promoters based on tumour biology (telomerase and VEGF 
promoters), which are reported to have a higher activity in tumour cells; tissue 
specific promoters (prostate specific antigen or PSA and probasin promoters in 
the case of prostate) and microenvironment responsive promoters (table 2) 
(Haviv and Curiel 2001; Robson and Hirst 2003). 
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Tumour biology specific Reference 
hTERT (Yu et al. 2011) 
MUC1 (Doloff et al. 2011) 
AFP (Ma et al. 2010) 
CEA (Fong et al. 2010) 
Prostate specific promoters  
PSA (Kraaij et al. 2007) 
PSMA (Coulter et al. 2010) 
Probasin (Trujillo et al. 2010) 
PPT (Danielsson et al. 2011) 
Microenvironment-specific promoters  
Flt-1 (Kaliberova et al. 2009) 
HRE elements (Kwon et al. 2010) 
GRP78 (Azatian et al. 2009) 
Table 2. Tumour, tissue and microenviroment-specific promoters used for gene therapy 
purposes.  
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In the case of prostate cancer gene therapy, the most common approach, given 
the characteristics of the prostate (particular gene expression profile and non-
vital function), is the use of tissue specific promoters. PSA, human kallikrein-2 
(hKLK2), probasin and prostate specific membrane antigen (PSMA) are some 
promoters currently under study to assess their therapeutic value in gene 
therapy. Nevertheless, the majority of these promoters show certain basal 
activity in other tissues or cell lines and weak expression when compared to 
strong promoters such as CMV (Latham et al. 2000; Yu et al. 2004). As a 
consequence, the engineering of prostate promoters through the addition or 
deletion of regulatory sequences has been the focus of many studies aiming to 
enhance the specificity and strength of prostate promoters. Recently a very 
elegant system for prostate specificity has been design by Woraratanadharm et 
al, in which a probasin-based promoter combined with a system regulated by 
tetracycline drives the transcription of EGFP (Woraratanadharm et al. 2007). 
This construction has been evaluated in two prostate cancer cell and two non-
prostate cancer cell lines with good results, but in vivo evidence is clearly 
needed. Another approach is to fuse different promoter regions and enhancers 
from two different prostate specific promoters. By fusing different sections of 
probasin and PSA promoters, Kraaij et al were able to diminish the length of a 
chimeric promoter and still maintain the tissue specificity, while improving the 
promoter activity when compared to a PSA parental promoter (Kraaij et al. 
2007). Another prostate specific promoter (PSMA), which is up-regulated by 
androgen deprivation, has been tested in two prostate cell lines and in induced 
tumours in mice, showing high specificity and low in vivo cytotoxicity (Zeng et al. 
2007).  
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1.9.5 Human prostate-specific transglutaminase 
The expression of the human prostate transglutaminase (hTGP) gene was 
found to be highly enriched in prostate tissue and indirectly regulated by 
androgens (Dubbink et al. 1998), and the minimal promoter region was mapped 
in the region -1 to -500 bp when tested in PC346C cells (Dubbink et al. 1998). 
In a later study it was found that a Sp1 binding-site in the proximal region of the 
promoter was necessary to induce transcription, and that the distal region of the 
2.1 kb promoter exerted a negative regulation on transcription. The tissue 
specificity region was mapped outside the 2.1 kb length promoter due to 
expression in several non-prostate cell lines (Dubbink et al. 1999a). Similar to 
other prostate specific genes, hTGP expression was found to be up-regulated in 
the more differentiated prostate epithelial cells (Dubbink et al. 1999b). Given the 
high specificity of this protein in prostate tissue, further characterization of the 
distal promoter could shed light on the regulatory mechanisms of prostate 
restricted expression. 
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2.	  AIMS	  OF	  RESEARCH	  
 
There is a need for novel therapeutic strategies to tackle prostate cancer, since 
traditional treatments such as radiotherapy, surgery and androgen deprivation 
therapy fail. A promising approach for prostate cancer is gene therapy, given 
that the prostate is a non-essential organ with a specific gene expression profile. 
In order to design effective gene therapy strategies, there are several things to 
consider. Primarily, there is the vector of gene delivery. Baculovirus is an 
excellent candidate and was chosen in this study because it transduces several 
mammalian and human cells, does not induce a memory immune response and 
can hold large amounts of genetic material. Secondly, there is the mechanism 
of therapy. In this case we chose to study the NTR/CB1954 system because of 
its capacity to induce cell death in proliferating and non-proliferating cells even 
at low transduction efficiencies. Thirdly, specificity and control of gene 
expression is highly important. The hTGP promoter was chosen because it is 
one of the most highly prostate-specific genes and its regulation does not 
depend directly on androgens. The main objective of this project was to 
construct a baculovirus gene therapy vector encoding the NTR suicide gene 
under the regulation of the hTGP promoter. 
 
Thus the main aims of this study were to: 
 
1. Determine the effectiveness of the NTR/CB1954 system in inducing cell 
death in prostate cancer cells. 
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2. Assess the efficiency of baculovirus transduction of prostate cell lines 
and primary prostate epithelial cells. 
3. Elucidate the factors and mechanisms regulating the hTGP gene 
expression, with a view to designing a prostate-specific promoter for use 
in a gene therapy vector. 
 
To achieve these goals, prostate cancer cell lines were transfected with NTR 
and treated with CB1954 to evaluate the cell death rate caused by this system. 
Prostate cell lines (malignant and non-malignant) and prostate primary epithelial 
cultures were transduced with baculovirus to analyse the transduction efficiency 
and the baculovirus’ ability to deliver the NTR gene and promote its expression. 
 
To study the hTGP promoter, a bioinformatic analysis was carried out to find 
putative responsive elements that could regulate hTGP expression. Prostate 
cell lines were treated with androgens and retinoic acid and tested for hTGP 
expression. To dissect the role of the AR and RAR in hTGP regulation, receptor 
specific siRNA was used to knockdown AR and RAR levels, and the effect on 
hTGP expression was evaluated. To confirm AR and RAR binding and activity 
the hTGP promoter sequence was cloned and receptor binding was assessed 
by chromatin immunoprecipitation. Finally a baculovirus vector encoding the 
NTR gene under the control of the hTGP promoter was constructed and was 
tested in prostate cancer cell lines for NTR expression and cell death following 
CB1954 treatment. 
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3.	  MATERIALS	  AND	  METHODS	  
 
3.1 Cell Culture 
3.1.1 Insect cell culture 
 
Sf9 cells were obtained from Invitrogen and culture as monolayers in Grace’s 
medium (Invitrogen), supplemented with 2mM L-Glutamine (Invitrogen) and 
10% FCS (PAA) at 27°C. Cells were subcultured at 70% confluence and media 
was replaced every 3 days.  
 
3.1.2 Human cell culture 
-Cell lines 
Human cell lines were purchased from either the American Type Culture 
Collection (ATCC, USA) or the European Collection of Animal cell culture 
(ECACC, UK) excluding PNT1A, PNT2C2 and P4E6 cells, which were 
established in our laboratory (Berthon et al. 1995; Maitland et al. 2001). 
PC346C cells were obtained from Dr. Robert Kraaij (Erasmus Medical Centre, 
The Netherlands). Tissue plasticware was purchased from Corning, and cells 
were routinely cultured in T25 flasks at 37°C with 5% CO2, unless high amounts 
of cells were required in which case cells were grown in T150 flasks under the 
same conditions. 
 
LNCaP, PNT1A and PNT2C2 were grown in Roswell Park Memorial Institute-
1640 medium (RPMI, Invitrogen) supplemented with 10% Foetal Calf Serum 
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(FCS, PAA) and 2mM L-Glutamine (Invitrogen). PC346C were cultured in 
Dulbecco’s Modified Eagle’s Medium (DMEM) (Invitrogen)/Ham’s F12 (Lonza) 
(1:1 volume) supplemented with 2% FCS, 100U/ml penicillin, 100µg/ml 
streptomycin, 0.01% (w/v) BSA (Sigma), 10ng/ml EGF (Sigma), 1% (v/v) ITS-G 
(GIBCO), 0.1nM R1881 (DuPont-New England Nuclear), 1.4µM hydrocortisone 
(Sigma), 1nM triiodothyronine (Sigma), 0.1nM phosphoethanolamine (Sigma), 
50ng/ml cholera toxin (Sigma), 0.1µg/ml fibronectin (Sigma) and 20µg/ml fetuin 
(Sigma). MCF7, T47D and HeLa cells were maintained in DMEM (Invitrogen) 
supplemented with 10% FCS and 2mM L-Glutamine. 
 
-Primary Cultures 
Patient samples were collected with ethical permission from York 
District Hospital (York) and Castle Hill Hospital (Cottingham, Hull). Prostate 
tissue was obtained only from patients who had given informed consent. Use of 
patient tissue was approved by the Local Research Ethics Committees. All 
patient samples were anonymised. Cells in culture were obtained from Dr 
Lindsay Georgopolus, Dr Fiona Frame, Dr Davide Pellacani, Dr April Frazer, 
Paula Kroon and Emma Oldridge. Cells were co-cultured on Collagen-I 
plasticware with irradiated STO murine feeder cells until growth was established 
in KSFM supplemented with 5ng/ml EGF, 50µg/ml bovine pituitary extract and 
2mM L-Glutamine. 
 
3.2 Foetal calf serum hormone depletion 
To remove steroid compounds and other lipid-based hormones, 2g of Norvid A 
charcoal (Sigma) were mixed with 100ml of FCS (PAA) and refrigerated at 4°C 
overnight. The mixture was centrifuged at 5000RPM for 10 minutes to 
	   68	  
precipitate the charcoal. Supernatant was repeatedly centrifuged at 5000RPM 
for 10 minutes until a clearer supernatant was visible. FCS was filtered using a 
0.2µm filter and stored at 4°C until used. 
 
3.3 SDS-PAGE and Western Blot 
Cells were lysed with Cytobuster (Novagen) for whole cell lysates, or with NE-
PER Nuclear and Cytoplasmic Extraction Reagent kit (Pierce) supplemented 
with 1X protease inhibitors (ROCHE) to obtain nuclear protein extracts. Before 
loading between 10-40µg of protein in each lane, samples were heated at 
100°C for 10 minutes then placed on ice for 2 minutes. 10% Tris-SDS 
acrylamide gel was used to resolve the proteins. Precision Plus Kaleidoscope 
standards ladder (Biorad) was used for sizing and visualization of gel running 
pattern and protein transfer. 
 
Resolved proteins were transfered into Immobilon-P membranes at 100V for 2h. 
Membranes were air-dried, wet with methanol, washed with TBS and blocked 
for 1h at room temperature (RT) in 1% (w/v) non-fat skimmed milk (Marvel) / 
TBS. Primary antibodies were diluted in 1% non-fat skimmed milk (Marvel) / 
TBS and incubated with the membranes for 1h at RT on a rocking table. 
Membranes were washed twice in TBS-Tween-20 0.1% (v/v) for 10 min 
followed by a wash in TBS and an incubation step in 0.5% non-fat skimmed 
milk (Marvel) / TBS for 15 minutes. Secondary antibodies were diluted in 0.5% 
non-fat skimmed milk (Marvel) / TBS and incubated for 1h at RT. After 
secondary antibody incubation, membranes were washed twice in TBS-Tween-
20 0.1% (v/v) for 10 minutes followed by a washing step in TBS for 15 minutes. 
	   69	  
HRP substrate (ROCHE) was added to the membranes followed by film 
(Hyperfilm ECL, Amersham) exposition. Films were manually processed using 
developer and fixer solutions (GBX, Kodak). 
 
3.4 RNA isolation and cDNA synthesis 
For RNA isolation the RNeasy Mini kit (Qiagen) was used according to 
manufacturer’s instructions. Briefly, cells were harvested, resuspended in PBS 
and centrifuged in 1.5ml eppendorf tubes at 5000RPM for 4 minutes. 
Supernatant was discarded and the cell pellet lysed and resuspended in RLT 
buffer, which contains guanidine thiocyanate supplemented with 1% β- 
mercaptoethanol. Cell lysates were homogenised using QIAshredder columns. 
1 volume of 100% ethanol was added to the homogenised lysates. The mixture 
was placed in RNeasy spin columns and centrifuged at 10000RPM for 30s to 
allow RNA binding to the column. After 2 washing steps the RNA was 
solubilised by adding H2O to the column followed by a 1 minute spin at 
10000RPM. For cDNA synthesis, 0.5-1µg total RNA was mixed with 50ng of 
random hexamer primers (Invitrogen) and 1µl of 2.5mM dNTPs mix (Invitrogen). 
The mixture was incubated at 65°C for 5 minutes then transferred to ice for 2 
minutes. To complete the cDNA synthesis reaction 5X First strand buffer 
(Invitrogen), DTT (0.1M), RNase inhibitor (RNaseOUT, Invitrogen, 40U/reaction) 
and reverse transcriptase (Superscript II, Invitrogen, 200U/reaction) were added. 
cDNA synthesis reactions were incubated at 25°C for 10 minutes followed by a 
42°C incubation for 50 minutes. To terminate the reaction samples were 
incubated at 70°C for 15 minutes. cDNA was purified using Qiagen’s QIAquick 
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PCR Purification Kit. RNA and cDNA concentration was measured using a 
nanodrop ND1000 spectrophotometer (Thermo Scientific). 
3.5 Generation of recombinant baculovirus 
Recombinant baculoviruses, where the EGFP and nitroreductase (NTR) 
enzyme are under the control of the cytomegalovirus early promoter (CMV), 
were constructed by Dr Stephanie Swift. Recombinant baculovirus bearing the 
hTGP promoter controlling the expression of the NTR enzyme was produced 
using the Bac-to-Bac Baculovirus Expression System (Invitrogen). NTR was 
amplified using the Expand High Fidelity PCR system (Roche) using previously 
described conditions and specific primers (Appendix B) that added XhoI and 
XbaI sites at the 5’ and 3’ end of the PCR product respectively. The hTGP4.5-
pGL3 plasmid was linearized using XhoI and XbaI enzymes (New England 
Biolabs) to create sticky ends.  
Linearized plasmid was separated by gel electrophoresis; the right size band 
cut and purified using the QIAquick Spin kit (Qiagen) following manufacturer’s 
protocol. Ligation reaction was set up using the Quick Ligation kit (New England 
Biolabs) combining 50ng of vector, 3-fold molar excess of insert Quick T4 DNA 
Ligase and incubating for 5 minutes at RT. DH5α bacteria (Invitrogen) were 
transformed with the ligation reaction and positive colonies screened by PCR 
using primers spanning the 5’ hTGP promoter and the 3’ NTR gene. PCR 
positive colonies were prepared and sent for sequencing to verify the integrity of 
the sequence. In order to clone the hTGP promoter-NTR enzyme sequences 
into the transfer vector pFASTBac1 (Invitrogen), SacI and XbaI enzymes (New 
England Biolabs) were used to excise this segment and linearized the vector. 
The removed fragment and the linearized pFASTBac1 vector were further 
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separated by gel electrophoresis and purified using the QIAquick Spin kit 
(QIAGEN).  
Ligation was set up using the Quick ligation kit (New England Biolabs) using 
previously described conditions. DH5α bacteria (Invitrogen) were transformed 
with the ligation reaction and positive colonies screened by PCR using primers 
spanning the 5’ hTGP promoter and the 3’ NTR gene and by transfecting 
LNCaP cells and screening for NTR expression by WB. Positive colonies were 
grown and plasmid purified and transformed into DH10Bac E.coli (Invitrogen). 
The DH10Bac strain contains a baculovirus shuttle vector and a helper plasmid 
and allows site-specific recombination into the baculovirus genome when the 
cells are transformed with the pFASTBac1 vector. DH10Bac colonies were 
screened by PCR using primers adjacent to the hTGP promoter-NTR 
sequences and primers within those sequences. Positive colonies were grown 
and plasmid isolated and purified for further transfection into sf9 insect cells. 4 
days after transfection, growing media containing recombinant baculovirus was 
centrifuged at 1300RPM, transfered to a 15ml Falcon tube and stored at 4°C. 
 
3.6 Virus titration 
Sf9 cells (1x106) were seeded in 6 well plates in duplicates 2 hours before viral 
infection. Serial dilutions of virus were prepared ranging from 10-2 to 10-6 for P1 
titres and from 10-4 to 10-8 for P2 titres in 1X Grace’s media supplemented with 
5% FCS, 12.5µg Fungizone, 500U penicillin and 5000U streptomycin. Medium 
was removed from insect cells and overlaid with 200µl of virus dilution and left 
for 1h at RT on a rocking table. Cells were overlaid with a 1:1 mix of 2% (w/v) 
agarose and growing media and left at RT for 30 min to allow the agarose to 
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solidify. Wells were covered with 2ml of growing media and placed in a 
humidified chamber at 28°C for 4-5 days to allow infection to proceed. Plaques 
were stained for 2h with 0.025% neutral red (Sigma) and left to dry overnight at 
28°C. A light box was used to identify and count lysis plaques. Titres were 
calculated on the basis of the average lysis plaques (in duplicate) and the 
dilution factor. 
 
3.7 Baculovirus amplification  
Sf9 cells (2x107) were seeded in T175 flasks (Corning) a day before the virus 
amplification. Cultures were infected for 1h with 0.1 pfu/cell diluted in 5ml of 
growing media on a rocking table. Infection was allowed to proceed for 5 days, 
then budded baculovirus in the supernatant was collected and centrifuged at 
1300RPM for 10 minutes to remove contaminating insect cells and debris. 
Supernatant was stored in the dark at 4°C. 
 
3.8 Viral DNA extraction 
Baculovirus DNA was extracted by mixing 10µl of concentrated baculovirus with 
89.4µl of virus lysis buffer (10mM Tris-HCl pH 8.3, 50mM KCl, 100µg/ml 
gelatine, 0.45% (v/v) Tween-20) and 0.6µl of proteinase K (10mg/ml). Mixture 
was incubated at 60°C for 1h, followed by an incubation step at 95°C for 10 
minutes, then allowed to cool to RT. A PCR reaction was set up using 2µl of 
viral lysate as template and specific primers spanning the hTGP promoter or the 
NTR gene to analyse the presence of the desired sequences. 
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3.9 Virus concentration 
Collected supernatant was ultracentrifuged at 24000RPM for 1h at 4°C using 
thinwall polyallomer tubes (Beckman) matched to a weight difference of 0.05g 
or less. Tubes were centrifuged in a LS-65 ultracentrifuge (Beckman) using the 
swing-out rotor SW28 (Beckman). After centrifugation supernatant was carefully 
removed leaving a white pellet. Pellet was overlaid with 1ml of PBS and left at 
4°C overnight for the pellet to dissipate. Concentrated virus was titred as 
previously described. 
 
3.10 Baculovirus transduction of human cells 
LNCaP, PC346C, PNT1A, PNT2C2, P4E6 and PC3 cells were seeded in 96 
well plates (1x105 cells/well) for MTS assay or in 48 well plates 2.2x105 for 
FACS analysis. Growing media was replaced with serum-free media containing 
500 pfu/cell and left incubating for 2h at 37°C unless otherwise specified. After 
incubation with the specific baculovirus, cells were added growing media and 
left for 24-72h at 37°C to allow transduction to proceed. Successful transduction 
was evaluated by western blot, MTS assay and/or FACS analysis depending on 
the recombinant baculovirus used.  
 
3.11 RT-PCR and RT-qPCR 
RT-PCR and RT-qPCR experiments were carried out using 10 and 50ng of 
cDNA/reaction as template, respectively. For qPCR experiments standard 
curves and primer efficiencies were evaluated to confirm the amplification of a 
single product and that the amplification efficiency was higher than 85%. 
Reactions for qPCR experiments were prepared in MicroAmp® Optical 96-Well 
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Reaction Plates (Applied Biosystems) using 10µl of Power SYBR Green 2X mix, 
50ng of cDNA, 1.5µl 10µM forward primer, 1.5µl 10µM reverse primer and H2O 
up to a total volume of 20µl. qPCR amplification experiments were run in 
triplicate on an ABI 7000 real-time PCR instrument and expression levels 
normalized to HPRT, which was used as a housekeeping gene. RT-PCR 
reactions were prepared in 0.2ml PCR tubes (Axygen) using the Platinum Taq 
DNA polymerase kit (Invitrogen). Reactions were prepared using 2.5µl 10X 
PCR Buffer, 0.5µl 10mM dNTP mixture, 0.75µl 10mM MgCl2, 0.5µl forward 
primer, 0.5µl reverse primer, 0.1µl Platinum Taq DNA polymerase, 1µl of cDNA 
(10/ng/µl) and 19.15 µl H2O. Reactions were run in the thermal block cycler 
GeneAmp PCR system 9700 (Applied Biosystems) and PCR products 
separated in 1-1.4% (w/v) agarose (Invitrogen) gels prepared with 1X TAE 
buffer (40mM Tris base, 1mM EDTA, 20mM Glacial Acetic Acid) and with 
GelRed (Biotium) at 1µl/ml to label DNA. Gels were visualized using the Gene 
Genious system (Syngene). 
 
3.12 Flow cytometry 
LNCaP, PC346C, PNT1A, PNT2C2, P4E6 and PC3 cells transfected with 
EGFP plasmid or transduced with Bv-EGFP were analysed by FACS to 
measure the number of EGFP positive cells. Cells were trypsinized, washed 
and resuspended in 500µl PBS and taken to the CyAn ADP for FACS analysis. 
At least 10,000 singlet events were recorded for each sample and each 
experiment was performed in duplicates. EGFP positive cells were analysed by 
plotting the FITC Log and the PE Log channels. 
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3.13 Gene expression profile in human tissues 
TissueScan Human Normal Tissue qPCR Arrays (OriGene Technologies, 
Rockville MD) were used to screen for hTGP, PSA and TMPRSS2 expression 
in 48 different tissues using Taqman gene expression assays Hs00162710_m1, 
Hs02576345_m1 and Hs01120965_m1 and following manufacturer’s 
instructions. 
 
3.14 Bacterial transformation 
Vials containing DH5α, Stbl3 or DH10Bac bacteria were thawed on ice for 30 
minutes before transformation. DH10Bac bacteria were aliquoted into separate 
tubes (100µl/tube). 1-5ng of plasmid DNA was added to each vial and left on ice 
for 30 minutes. Cells were heat-shocked for 45s at 42°C without shaking. Cells 
were then placed on ice for 2 minutes, followed by the addition of 250µl (DH5α 
and Stbl3) or 900µl (DH10Bac) of RT SOC medium (Invitrogen). Vials were 
incubated at 37°C for 1h (DH5α and Stbl3) or 4h (DH10Bac) in a shaking 
incubator. DH5α and Stbl3 cells were plated in LB agar plates containing either 
30µg/ml Kanamycin or 50µg/ml Penicillin and incubated for 24h before colony 
screening. DH10Bac cells were plated in LB agar plates containing 50µg/ml 
Kanamycin, 7µg/ml gentamycin, 10µg/ml Tetracyclin, 100µg/ml X-gal and 
40µg/ml IPTG and left at 37°C for at least 48h to allow white/blue colouring of 
the colonies. 
 
3.15 Bacterial cultures, plasmid isolation and purification 
E. coli strains DH5α (Invitrogen), stbl3 (Invitrogen) and DH10Bac (Invitrogen) 
containing plasmids of interest were grown in LB liquid media (tryptone, yeast 
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extract and NaCl) overnight in the presence of specific antibiotics; ampicillin, 
kanamycin, gentamicin. Bacterial cultures were centrifuged at 4,500RPM and 
supernatant discarded. Cell pellets were resuspended using Qiagen’s buffer P1 
(50mM Tris-Cl pH 8.0, 10mM EDTA, 100µg/ml RNase A). Buffer P2 (200nM 
NaOH, 1% SDS (w/v)) was added to the mixture and mixed thoroughly by 
gently inverting the containing tube and left at RT for 5 minutes. Buffer P3 (3.0M 
potassium acetate, pH 5.5) was added and mixed by gently inverting the tube 
until a clear phase and a precipitate could be visible. The mixture was 
incubated in ice for 15 minutes, then centrifuged at 14000RPM for 30 minutes 
at 4°C. Supernatant was applied to the QIAGEN-tip to promote plasmid binding 
to the tip’s resin, followed by a series of washing steps with buffer QC (1.0M 
NaCl, 50mM MOPS pH7.0, 15% isopropanol (v/v), 0.15% Triton X-100 (v/v)). 
Plasmid DNA was eluted using QF buffer (1.25M NaCl, 50mM Tris-Cl pH 8.5, 
15% isopropanol (v/v)) and precipitated by adding 0.7 volumes of isopropanol 
and centrifuging at 14000RPM for 1h at 4°C. DNA pellet was washed with 70% 
ethanol (v/v) at RT, then resuspended in H2O. 
 
3.16 Generation of hTGP promoter constructs 
The hTGP promoter sequence (4.5 kb) was amplified using the Expand High 
Fidelity PCR system (Roche), using specific primers (see appendix B) and the 
manufacturer’s protocol. Briefly, template DNA (2ng) were mixed with specific 
primers (300nM), dNTPs (200µM), 10X Polymerase buffer and Expand High 
Fidelity enzyme mix (2.6U/reaction) in a total volume of 50µl. Samples were 
placed in the thermal block cycler GeneAmp PCR system 9700 (Applied 
Biosystems) using the following thermal profile: 1 cycle at 94°C for 2 minutes, 
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30 cycles of 15s at 94°C, 30s at 55°C and 4 minutes at 68°C and a final 
elongation step of 7 minutes at 68°C. Amplified hTGP promoter was cloned into 
the pEGFP-1 plasmid (Clontech) using the restriction enzymes XhoI and SacII 
(New England Biolabs).  To clone the hTGp (4.5 kb) and the several deletion 
mutants into the pGL3 basic vector (Promega), the In Fusion cloning system 
(Clontech) was used following manufacturer’s protocol (see appendix for 
primers sequence). Briefly, primers spanning the hTGP promoter were design 
to amplify the 4.5kb section, previously cloned into the pEGFP-1 plasmid and 
shorter versions (3.5, 3, 2.5, 2 and 1.5 kb, respectively). Amplification was 
carried out using the Expand High Fidelity PCR system (Roche) using the same 
conditions previously described. PCR products were ligated into the pGL3-basic 
plasmid using the In-Fusion kit enzymes and buffers. 1µl of ligation reaction 
was used to transform STBL3 (Invitrogen) chemically competent E. coli. All 
sections of the promoter that involved PCR amplification were subject to DNA 
sequencing to confirm the fidelity of the amplification. 	  
3.17 Immunofluorescence  
PC346C or LNCaP cells were seeded in Poly-D-lysine 8-well CultureSlides (BD) 
in charcoal stripped media for 48h. Before fixation, cells were briefly washed 
with PBS, fixed by adding cold methanol (-20°C) for 5 min, and then air-dried. 
Incubation in 10% goat serum (Sigma) for 1h was used to block non-specific 
antibody binding. Cells were incubated with AR antibody (sc-816) or IgG rabbit 
isotype (Sigma) as negative control in 1% BSA/PBS for 1h at room temperature. 
Secondary antibody goat anti-rabbit labelled with Alexa Fluor 488 (Invitrogen) 
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was incubated for 30 minutes in 1% BSA/PBS at room temperature. Slides were 
mounted with DAPI-containing VECTASHIELD (Vector Laboratories). 
 
3.18 Plasmid transfection into human cell lines 
Cells were seeded in 96- or 6-well plates and grown either in complete media 
(for NTR transfection) or charcoal stripped media (for hTGP promoter or retinoic 
acid sensitivity evaluation) for 24h previous to transfection. To measure retinoic 
acid responsiveness, Cignal RARE reporter (luc) kit plasmids (CCS-016L) from 
SABiosciences were transfected into LNCaP, PC346C, PNT1A and PNT2C2 
cells using TransIT-LT1 for PC346C and PNT1A, PNT2C2 and TransIT-2020 
for LNCaP cells as transfection reagents. Cells were transfected using a 
DNA:Transfection reagent ratio of 1:3 (µg:µl). For cells growing in 96 wells a 
total of 250ng of plasmid/well produced the best transfection efficiency, while for 
cells growing in 6-well plates 2.5µg were required to achieve the best 
percentage of transfected cells. Cells were treated with either vehicle (DMSO) 
or atRA (500nM) 18h after transfection and luciferase activity measured after a 
further 24h.  For the functional analysis of the hTGp promoter, plasmid mixtures 
containing the different versions of the hTGP promoter and the pRL-CMV 
Vector (Promega) (in a 1:1 copy number ratio) were co-transfected into LNCaP 
cells grown for 24h in charcoal stripped media, using TransIT-2020 as a 
transfection reagent. 12h after transfection cells were treated with vehicle 
(DMSO), atRA (500nM) or R1881 (10nM) for a further 24h.  
 
 
 
	   79	  
3.19 Plasmid transfection into Sf9 insect cells 
Sf9 cells (8X105) were seeded in 6 well plates in 1:1 (v/v) growing media 
without antibiotics and unsupplemented Grace’s Insect medium (without serum) 
30 minutes before transfection. Baculovirus DNA (1µg) and 8µl of Cellfectin II 
(Invitrogen) were mixed separately with 100µl of unsupplemented Grace’s 
Insect Medium. Diluted DNA and Cellfectin II were mixed by pipetting and left at 
RT for 15-30 minutes. The DNA-lipid mixture was then added drop wise to the 
cells and left at 28°C for 3-5h. Transfection mixture was removed and replaced 
with complete growing media supplemented with antibiotics, and incubated for 
72h or after signs of viral infection were clearly visible. 
 
3.20 Luciferase assay 
Luciferase expression was measured using the Dual-Glo system (Promega) 
following manufacturer’s protocol and the Polarstar Optima micro-plate reader 
(BMG). Lysis buffer containing luciferase substrate (1:1 v/v) was added to cells 
growing in 96 well plates and mixed by pipetting. Luciferase activity was 
measured 10 minutes after cell lysis. Stop & Glo reagent was added to the wells 
to quench luciferase activity and provide substrate for Renilla luciferase. Renilla 
luciferase activity was measured 10 minutes after Stop & Glo reagent addition. 
 
3.21 MTS assay 
CellTiter 96 AQueous One Solution Reagent (Promega) was thawed at RT 
before use. For cells growing in 100µl medium in 96 well plates, 20µl of 
CellTiter reagent were added and cells incubated at 37°C for 2-4h. As 
background controls wells containing cells without CellTiter reagent were used. 
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Absorbance was recorded at 490nm using a BMG Labtech POLARstar OPTIMA 
microplate reader. 
 
3.22 siRNA transfection 
LNCaP cells were grown in charcoal-stripped media for 24h in 6-well plates 
coated with L-Poly-lysine (Sigma) before transfection. A 2.5µM siRNA solution 
was prepared in RNase-free H2O. In separate tubes siRNA and DharamaFECT 
2 transfection reagent (Dharmacon), 3µl of reagent for every 2X105 cells, were 
diluted using serum-free medium. Diluted siRNA and transfection reagent were 
mixed and left at RT for 20 minutes. Adding growing medium until reaching the 
desired final volume completed the transfection mix. The siRNA final 
concentration was 12.5nM per experiment. The specific siRNAs used were 
Silencer select (Applied Biosystems) siRNAs targeting RARB (siRNA ID: 
s11804), RARG (siRNA ID: s11807), AR (siRNA ID: s1538) or Negative control 
♯1. Cells were harvested every 24, 48 and 72h for RNA extraction or every 48, 
72 and 96h for protein extraction. 
 
3.23 NTR half-life 
LNCaP cells were transfected with the hTGP-NTR plasmid while growing in T25 
flasks following the same basic procedure as previously described, but 
increasing the quantity of plasmid DNA to 6.5µg. 24h after transfection the cells 
were trypsinized and plated in 6-well plates (3X105 cells/well, 2 wells per time 
point) in the presence of atRA 500nM to stimulate NTR expression. 48h 
following atRA addition, cells were treated with 120µg/ml cyclohexamide 
(Sigma) and harvested every 2h up to 10h. Proteins were extracted and SDS-
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PAGE followed by western blot to measure the levels of NTR after 
cyclohexamide treatment. As a positive control a western blot evaluating α-
clusterin expression was performed using the Anti-clusterin α chain antibody 
(clone 41D, Millipore). β-actin levels were measured as a loading control and 
semi-quantitative densitometry performed using GelEval software (FrogDance). 
 
3.24 Chromatin Immunoprecipitation (ChIP) 
Cells were grown in T175 flasks in charcoal stripped media for 24h, then treated 
with either atRA (500nM), R1881 (10nM) or vehicle (DMSO) for 10h. After 
treatments cells were trypsinized and resuspended in 5ml media and treated 
with fomaldehyde to a final concentration of 1% for 10 minutes at RT with gentle 
shaking. Glycine was added to stop fixation to a final concentration of 0.125 M 
for 5 minutes at RT. Cells were washed with cold PBS and resuspended in cold 
swelling buffer (5mM Pipes pH 8, 85mM KCl) supplemented with NP-40 (final 
concentration of 0.2%) and protease inhibitors (Roche). The cell suspension 
was incubated in ice with gentle shaking for 20 minutes. Suspension was 
centrifuged at 3,000 rpm and resuspended in IP buffer TSE150 (0.1% SDS, 1% 
Triton, 2mM EDTA, 20mM Tris-HCl pH 8, 150mM NaCl) supplemented with 
protease inhibitors (Roche) and sonicated using a Bandelin Sonopuls HD 2070, 
for 21 cycles of 30s on/30s off at full power. Chromatin was centrifuged at 
14,000RPM for 30 minutes, aliquoted and stored at -80°C. A sample of the 
sonicated chromatin was purified using a phenol/chloroform extraction to 
corroborate correct chromatin disruption. Protein A-sepharose beads (Sigma) 
were blocked by incubating them in an IP buffer TSE150 solution containing 
yeast tRNA (Sigma) to a final concentration of 1µg/ml and BSA (Sigma) to a 
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final concentration of 250µg/ml while rotating at 4°C for 4h. Chromatin was 
cleaned up by incubating 50µl of 50% pre-blocked protein A-sepharose beads 
with 20µg/IP of chromatin in a total volume of 1 ml TSE 150 buffer for 1.5h at 
4°C while rotating. The suspension was centrifuged for 1 minute at 3,000 rpm 
and supernatant kept in a separate tube. 20 µl of the supernatant were kept to 
be used as INPUT control, then the rest was divided and incubated with either 
anti-RAR (sc-773), AR (sc-816) (Santa Cruz Biotech) or purified rabbit IgG 
(PP64B Millipore) at 4°C overnight. Antibody-protein-DNA complexes were 
recovered by incubation with 50µl of 50% pre-blocked protein A sepharose 
beads for 1.5h at 4°C. Beads were retrieved by centrifugation at 3,000 rpm for 1 
minute at RT and washed with IP buffer TSE150, IP buffer TSE500 (0.1% SDS, 
1% Triton, 2mM EDTA, 20mM Tris-HCl pH 8, 500mM NaCl), washing buffer 
(10mM Tris-HCl pH 8, 0.25M LiCl, 0.5% NP-40) and TE buffer (10mM Tris-HCl 
pH 8, 1mM EDTA). DNA was eluted by adding 100µl of elution buffer (1% SDS, 
10mM EDTA, 50mM Tris-HCl pH 8) and an incubation step at 65°C for 15 
minutes. Beads were centrifuged at 15,000RPM for 1 minute and supernatant 
transfered to a separate tube. Beads were rinsed with 150µl TE/1% SDS, 
vortexed, centrifuged at 15,000RPM and the supernatant pooled with the 
previous one. Immunoprecipitated DNA was left at 65°C overnight, then treated 
with proteinase K (Invitrogen) together with glycogen (Roche) for 2 h. DNA was 
purified by phenol/chloroform extraction. The percentage of 
Immunoprecipitation (%IP) was calculated taking into account the dilution factor 
and the level of amplification obtained from unprecipitated chromatin. 
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4.	  RESULTS	  
 
4.1 Efficiency of the NTR/CB1954 system in prostate cells 
4.1.1 Determining prostate cell lines’ sensitivity to CB1954 
In order to test the efficiency of the NTR/CB1954 system in prostate cell lines, it 
was necessary to determine the optimal concentration of CB1954 to treat each 
cell line. PNT1A, PNT2C2 (benign cell lines), P4E6 (early-stage cancer), PC3, 
LNCaP and PC346C (malignant cell lines) were treated with increasing 
concentrations of the prodrug CB1954 (from 5 to 40µM) for a period of 72h. 
Following the incubation period, cells were tested for viability using the MTS 
assay that measures the cells’ metabolic activity, which is correlated to their 
survival. Figure 10 shows the relative survival of the different cell lines. P4E6 
and PNT2C2 showed high sensitivity to the CB1954 drug, displaying a 
decrease of 26% and 31% in relative survival, respectively, at 40µM. PC3, 
PC346C, LNCaP and PNT1A showed less sensitivity to CB1954 with a drop in 
relative survival between 7%-18% at 40µM. Based on these results, a 10µM 
concentration for P4E6 and PNT2C2 cells and 20µM for LNCaP, PC3, PC346C 
and PNT1A cells were chosen. All further experiments using CB1954 were 
conducted using these selected concentrations for each cell line to prevent 
unspecific toxicity caused by the prodrug treatment in the absence of enzyme. 
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 Figure 10. Determining prostate cell lines sensitivity to CB1954. Prostate cell lines P4E6, PNT2C2, PC3, PNT1A, LNCaP and PC346C were treated with CB1954 for 72h.
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4.1.2 NTR expression in prostate cancer cells triggers cell death after 
CB1954 treatment. 
To determine the susceptibility of prostate cancer cells to the NTR/CB1954 pro-
drug system, PC3 and P4E6 cells were transiently transfected with two 
plasmids bearing either the wild-type NTR gene or a mutated version that 
confers higher enzymatic activity (NTR-mutant), under the control of the CMV 
promoter. Western blot analysis of NTR expression 24h after transfection (figure 
A) showed that both cell lines expressed high levels of NTR, either WT or 
mutant. To test whether the enzyme expressed in these cell lines was capable 
of catalysing the reduction of the CB1954 pro-drug, thus transforming it into a 
very powerful cytotoxic compound, transfected P4E6 cells were treated with 
CB1954 for 72h. P4E623A cells stably transfected with NTR-mutant were used 
as a positive control. Figure 11B shows that only cells that were transfected with 
either NTR WT or NTR-mutant and treated with CB1954 display decreased cell 
viability, which was comparable to the effect seen in P4E623A cells. Cells 
transfected with EGFP and treated with CB1954 showed a small decrease in 
cell viability most likely caused by the known EGFP toxicity (Liu et al. 1999). 
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Figure 11.	  NTR enzyme expression in prostate cancer cell lines and induction of cell death after CB1954 treatment. A. Western Blot of NTR (WT and mutant) 
expression in transfected P4E6 and PC3 prostate cancer cell lines. β-actin was used as loading control. P4E623A are P4E6 cells stably transfected with a 
CMV-NTR plasmid. Lanes: 1. NTR WT 24h 2. NTR MUT 24h 3. EGFP 24h 4. NTR WT 48h 5. NTR MUT 48h 6. EGFP 48h. B. Cell viability, as measured by 
MTS assay, of P4E6 cells transfected with NTR (WT and mutant) 72h after CB1954 treatment (10µM). 
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4.2 Baculovirus as a vector for prostate cancer gene therapy 
 
4.2.1 Baculovirus effectively transduces prostate cancer cell lines 
A panel of malignant and benign prostate cell lines were transduced with the 
recombinant baculovirus BV-EGFP which encodes the enhanced green-
fluorescent protein (EGFP) under the control of the CMV promoter, to assess 
the transduction efficiency of the baculovirus in prostate cells. EGFP positive 
cells were counted 24h post-transduction, using FACS analysis and the results 
presented as a percentage of EGFP positive cells. Figure 12A shows that BV-
EGFP effectively transduces prostate cancer cell lines LNCaP, PC346C and 
PC3, while early-stage cancer cell line P4E6 and benign cell lines PNT1A and 
PNT2C2 show low levels of EGFP expression. The same panel of cell lines 
were transduced with a recombinant baculovirus encoding the NTR-mutant 
gene under the control of the CMV promoter and 24h after transduction treated 
with CB1954 for a further 72h to evaluate cell viability. Prostate cancer cell lines 
LNCaP, PC346C and PC3 displayed massively decreased viability after 
CB1954 treatment (80% reduction, figure 12B). PNT1A and PNT2C2 cells 
showed high percentage of viable cells, with a reduction in cell viability of less 
than 20%, while P4E6 showed a decrease of almost 40% in cell viability. Cell 
viability after CB1954 treatment matched the transduction efficiency for each 
cell line, where the more efficiently transduced cell lines displayed higher cell 
death caused by the NTR enzymatic activity in the presence of CB1954. 
Interestingly, baculovirus seemed to be more effective at transducing malignant 
prostate cell lines than benign cell lines. This “preference” is displayed 
regardless of the differentiation status and proliferation rate of each cell line. 
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LNCaP and PC346C cells are more differentiated cells than PC3 (Table 3). 
They express AR, and PSA expression is stimulated by androgen treatment. 
The doubling time of P4E6, PC3, PNT1A and PNT2C2 is less than the doubling 
time for LNCaP and PC346C cells (Table 3). Therefore, the main difference 
between permissive and non-permissive cells could lie in the internal 
mechanisms that transport the baculovirus from the cytoplasm into the cell’s 
nucleus. It has been reported that in HeLa cells transduced with baculovirus, 
the majority of the virus remains trapped in intracellular vesicles and is unable 
to reach the nucleus (Barsoum et al. 1997). This observation stresses the 
importance of effective endosomal escape in baculovirus transduction.  
 
These results suggest that the baculovirus is able to deliver the NTR gene to 
prostate cancer cells and has the ability to transduce prostate cancer cell lines 
more efficiently than non-malignant cells. 
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Table 3. Differentiation markers and doubling times of prostate cell lines. 
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Figure 12. Baculovirus effectively transduces prostate cancer cell lines. A. Percentage of EGFP 
positive cells 24h after being transduced with a recombinant baculovirus encoding the EGFP 
gene (BV-EGFP) under the control of the CMV promoter as measured by FACS analysis. B. 
Cell viability, as measured by MTS assay, in cells transduced with a recombinant baculovirus 
encoding the NTR-mutant gene (BV-NTR), under the control of the CMV promoted and treated 
with CB1954 for 72h. 
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4.2.2 Baculovirus can efficiently transduce cultured cells derived from 
patients. 
While the baculovirus showed a high transduction efficiency in human prostate 
cancer cell lines, it was also necessary to test its ability to transduce a more 
clinically relevant model such as cultured cells derived from patient tissue. Cells 
were seeded in collagen-coated wells and transduced with BV-NTR. As one of 
the controls, cells were transduced with the BV-EGFP and images of EGFP 
positive cells were taken 24h after transduction. CB1954 pro-drug was added 
24h after transduction and the cells remained in culture for 48h before 
performing the MTS assay. Figure 13A shows data from three different primary 
samples transduced with the BV-EGFP. All samples showed the presence of 
EGFP positive cells indicating that the transduction was successful. Figure 13B 
shows the cell viability 48h after CB1954 addition in cancer and BPH samples. 
Noticeably there is no obvious difference between cancer and benign cultures, 
in contrast to the differences described in cell lines, suggesting that benign and 
cancerous prostate cells could be transduced equally.  
Taken together, these encouraging results provide evidence of the potential for 
successful use in gene therapy of baculovirus in delivering the NTR enzyme 
into prostate epithelial cell lines and cultured cells derived from patients. 
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Figure 13. Patient-derived prostate cells grown in vitro are susceptible to baculovirus transduction. A. Patient-derived cells transduced with BV-EGFP showing fluorescent 
protein expression after 24h. PE28-07=cancer sample, PE11-07=castration resistant, PE008-06= cancer sample. B. Cell viability, as measured by MTS assay, in malignant 
and benign patient-derived prostate cells transduced with BV-NTR and treated with CB-1954 (20µM) for 48h. 
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4.3 hTGP promoter characterization 
 
4.3.1 hTGP expression is highly prostate specific 
In order to construct a successful gene therapy vector one of the most 
important characteristics is a tightly regulated tissue-specific promoter. For this 
the hTGP promoter was chosen as a potential prostate-specific promoter for 
use in our system. 
Previous reports suggested that hTGP expression was restricted to the prostate 
using Northern blot analysis (Dubbink et al. 1998). To expand on this finding 
and quantitatively compare hTGP expression to that of other known prostate-
specific genes such as PSA and TMPRSS2, a cDNA qPCR-array containing 
cDNA samples from 48 different healthy human tissues was carried out. Figure 
14 shows the expression levels of hTGP, PSA and TMPRSS2 in a panel of 
different human tissues. hTGP expression is almost 200 times higher in the 
prostate than in the next highly expressing tissue, the testis. In total hTGP 
expression was detected in 21/48 tissues. While PSA expression was more 
than 400 times higher in the prostate than in the next highly expressing tissue 
(fat), PSA was detected in 32/48 tissues, suggesting that although hTGP could 
be less abundant in the prostate than PSA, it is crucially more prostate-specific. 
TMPRSS2 expression was highest in the prostate, but was surprisingly also 
detected in high levels in different tissues such as colon, pancreas, stomach 
and lungs (figure 14). TMPRSS2 mRNA expression could be detected in 39/48 
tissues, casting serious doubts on what is considered to be a prostate-specific 
gene. 
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Figure 14. hTGP, PSA and TMPRSS2 mRNA expression profile in human tissues. Expression values were normalized to the second highest expressing 
tissue. 
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4.3.2 hTGP expression in prostate cell lines is controlled by retinoic acid 
Previous reports suggested that androgens indirectly regulated hTGP 
expression in the prostate cancer cell line PC346C and that the elements 
responsible for this regulation were outside the 2.1kb proximal promoter 
characterized at this time (Dubbink et al. 1996; Dubbink et al. 1999a). It was 
therefore decided to carry out a bioinformatic analysis on a larger, 4.5kB portion 
of the hTGP in order to find putative binding sites for transcription factors 
important in prostate-specific expression. Figure 15A shows a schematic 
representation of AREs and RAREs found in the 4.5kb hTGP promoter and 
figure 15B shows the consensus sequences used to search for AREs and 
RAREs.  
 
As mentioned in the introduction, AR and RARs play important roles in prostate 
development and homeostasis and thus it was decided to investigate the role of 
both receptors in the regulation of hTGP expression. A panel of prostate cell 
lines were treated with 500nM all trans retinoic acid (atRA) for 24h, and hTGP 
mRNA expression was assessed. Figure 15C shows that hTGP expression 
increased in LNCaP and PC346C in response to atRA treatment, while PNT1A 
and PNT2C2 cells showed a decrease in hTGP expression. To investigate the 
kinetics of the response seen in hTGP expression to atRA in LNCaP cells, RNA 
samples from LNCaP cells treated with 500nM atRA were taken after incubation 
time-points between 2-24h. hTGP expression significantly increased 4h after 
atRA treatment and continued increasing up to 24h after the start of the 
treatment (figure 15D). Such a rapid response suggested that the effect of atRA 
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on hTGP expression was caused directly by the activity of a receptor stimulated 
by atRA, most likely the RARs. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	   97	  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
-­‐1	  kb -­‐2	  kb -­‐3	  kb -­‐4	  kb 
	   	   	   	  
	   	  ARE RARE 
	   	  
RARE 
ARE 
0.1	  
1	  
10	  
100	  
Mock	   atRA	   Mock	   atRA	   Mock	   atRA	   Mock	   atRA	  
hT
Gp
	  m
RN
A	  
re
la
ti
ve
	  e
xp
re
ss
io
n	  
LNCaP PC346C PNT1A PNT2C2 
* 
* 
* 
* 
A	  
B	  
C	  
	   98	  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15.	  Retinoic acid regulates hTGP mRNA expression in prostate cell lines. A. Depiction of 
AREs and RAREs found in a 4.5kb portion of the hTGP promoter by bioinformatics analysis 
using the JASPAR database. B. Graphic representation of the consensus sequences used to 
determine AREs and RAREs in the hTGP promoter (taken from the JASPAR database website). 
C. hTGP mRNA expression in prostate cell lines LNCaP, PC346C, PNT1A and PNT2C2 treated 
with either 500nM atRA or vehicle for 24h as measured by qPCR. D. hTGP mRNA levels in 
LNCaP cells treated with 500nM atRA between 2-24h. The symbol * denotes statistical 
significance respect to control as measured by Student-T test (p<0.05).  
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4.3.3 Prostate cell lines have different abilities to activate transcription 
following atRA treatment 
LNCaP and PC346C cells were shown to increase hTGP mRNA levels following 
atRA treatment, while PNT1A and PNT2C2 cells displayed decreased hTGP 
expression. To find out differences between the cell lines that could explain this 
differential regulation, total RAR protein levels and mRNA levels of RAR 
isoforms were evaluated. It was hypothesised that different RAR expression 
levels or expression of certain RAR isoform(s) could be responsible for the 
distinct hTGP regulation between cell lines. To test this hypothesis, western blot 
analysis evaluating RAR expression in LNCaP, PC346C, PNT1A and PNT2C2 
was carried out. Figure 16A shows that total RAR protein levels were higher in 
PNT1A and PNT2C2 cells, meaning that the differential response of hTGP to 
atRA  was not due to a lack of RAR expression driving.  
 
RARA, RARB and RARG mRNA levels across the panel of prostate cell lines 
did not produce a clear pattern, suggesting that preferential expression of one 
or more isoforms could be responsible for the differences between the cell lines’ 
response to atRA treatment regarding hTGP expression (figure 16B). 
 
To test the overall ability of each cell line to activate transcription following atRA 
treatment, prostate cell lines were transfected with a luciferase reporter plasmid 
where the active regulatory element is composed of a TATA box element and a 
tandem of RAREs, that upon ligand-bound RAR recognition and binding 
activate luciferase transcription (figure 16C). At 18h after transfection cells were 
treated with increasing concentrations of atRA, and luciferase activity measured 
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after a further 24h. LNCaP and PC346C were able to activate luciferase 
expression following atRA treatment reaching 10.6- and 15.7-fold induction, 
respectively when cells were treated with 1µM atRA (figure 16D upper panels). 
PNT1A and PNT2C2 cells also showed an increase in luciferase expression 
following atRA treatments, 2.8- and 4.5-fold increase, respectively (figure 16D 
bottom panels). However, the magnitude of this increase was modest when 
compared to that of LNCaP and PC346C after atRA induction. 
These results suggested a correlation between the ability of the cell lines to 
induce transcription in response to atRA treatment and the induction of hTGP 
expression after atRA treatment. More interestingly was the observation that 
LNCaP and PC346C cells, which activate hTGP expression after atRA 
treatment, possess characteristics of a more differentiated cell type (AR and 
PSA expression), while PNT1A and PNT2C2 are less differentiated. This has 
more relevance since hTGP expression was only detected in the luminal 
compartment of the prostate (Dubbink et al. 1999b), meaning that it was 
expressed exclusively by more differentiated cells. Our results suggest that 
there is a differential regulation of hTGP expression depending on the 
differentiation status, which is supported by previous reports. 
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Figure 16. Differential regulation of hTGP expression could be caused by differential transcriptional activity in response to atRA treatment. A. Western blot 
analysis of RARs in LNCaP, PC346C, PNT1A and PNT2C2. β-actin was used as a loading control. B. RAR isoforms mRNA expression profile in LNCaP, 
PC346C, PNT1A and PNT2C2 cells measured by qPCR. C. RARE reporter and control plasmids depicting regulatory elements. D. Luciferase activity in 
transfected prostate cell lines in response to increasing concentrations of atRA. Luciferase activity was normalised to the values of the cells transfected with 
the negative control and treated with 1µM atRA. The symbol * denotes statistical significance with respect to control as measured by Student-T test (p<0.05).
D
0	  5	  
10	  15	  
20	  
Vehicle	   	  atRA	  1	  µM	   Vehicle	   	  atRA	  250	  nM	   atRA	  500	  nM	   atRA	  1µM	  Rel
at
iv
e	  
lu
ci
fe
ra
se
	  
ac
ti
vi
ty
	  
0	  5	  
10	  15	  
20	  
Vehicle	   atRA	  1	  µM	   Vehicle	   atRA	  250	  nM	   atRA	  500	  nM	   atRA	  1	  µM	  Rel
at
iv
e	  
lu
ci
fe
ra
se
	  
ac
ti
vi
ty
	  
Negative RARE	  plasmid Negative RARE	  plasmid 
0	  5	  
10	  15	  
20	  
Vehicle	   atRA	  1µM	   Vehicle	   atRA	  250nM	   atRA	  500nM	   atRA	  1	  µM	  Rel
at
iv
e	  
lu
ci
fe
ra
se
	  
ac
ti
vi
ty
	  
LNCaP PC346C 
PNT1A 
Negative RARE	  plasmid 
0	  5	  
10	  15	  
20	  
Vehicle	   atRA	  1µM	   Vehicle	   atRA	  250nM	   atRA	  500nM	   atRA	  1µM	  Rel
at
iv
e	  
lu
ci
fe
ra
se
	  
ac
ti
vi
ty
	  
Negative RARE	  plasmid 
PNT2C2 
* * 
* * * * * * 
	   103	  
4.3.4 hTGP expression is repressed by androgens 
Once it was established that hTGP expression could be regulated by 
atRA, it was decided to test the effect of androgens on the regulation of 
hTGP expression. For this purpose, AR expressing cells LNCaP and 
PC346C were treated with increasing concentrations of the synthetic 
androgen R1881 for 24h. hTGp expression decreased after R1881 
treatments in both LNCaP and PC346C cells (figure 17A). Because 
R1881 and atRA had opposing effects on hTGP expression, it was 
decided to co-treat LNCaP and PC346C cells with R1881 and atRA 
together to evaluate whether the positive effect of atRA could antagonize 
the negative effect of R1881 on hTGP expression or vice versa. Figure 
17B shows RT-PCR analysis of hTGP mRNA levels in LNCaP and 
PC346C cells either treated with atRA, R1881 or a combination of both 
compounds. As a positive control for R1881 treatments, PSA expression, 
known to be up-regulated by androgens, was monitored. As previously 
seen, hTGP mRNA levels in untreated cells were higher in PC346C than 
in LNCaP (figure 17B). After atRA treatment hTGP mRNA levels 
increased in both cell lines (compare lanes 5 and 6). However when the 
cells were co-treated with atRA and R1881, induction of hTGP mRNA 
was completely disrupted in LNCaP cells, while in PC346C hTGP mRNA 
levels decreased (figure 17C). These results indicated that androgen 
treatment was capable of cancelling the positive effect of atRA on hTGP 
expression. 
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Figure 17. Androgens have a negative effect on hTGP mRNA expression. A. LNCaP and PC346C hTGP mRNA expression 24h after 10nM R1881 or vehicle 
treatments. B. hTGP, PSA and GAPDH mRNA expression in LNCaP and PC346C cells treated with 500nM atRA, 10nM R1881 or a combination of both 
hormones for 24h. The symbol * denotes statistical significance with respect to control as measured by Student-T test (p<0.05). 
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4.3.5 AR knockdown does not rescue hTGP expression after R1881 
treatment in LNCaP cells 
LNCaP cells were transfected with AR-specific siRNA to evaluate the effect of 
this protein knockdown in hTGP expression both in basal conditions and 
following R1881 treatment. AR mRNA was successfully knocked down (75% 
knockdown) following AR-specific siRNA transfection in LNCaP cells (figure 
18A). AR protein also suffered a significant knockdown, as measured by 
western blot analysis, where AR protein could not be detected (figure 18B). AR 
knockdown in LNCaP cells was expected to rescue hTGP mRNA expression 
since androgen treatments decreased hTGP expression. However, AR 
knockdown did not result in hTGP expression rescue, but in a further repression 
of hTGP mRNA expression in basal conditions and following R1881 treatment 
(figure 18C). 
 
 
 
 
 
 
 
 
 
 
 
 
	   107	  
 
 
 
 
 
 
 
 
 
 
 
Figure 18. AR knockdown affects hTGP expression. A. AR mRNA expression in LNCaP cells 
transfected with AR-specific siRNA and treated with 10nM R1881 or vehicle as control. B. AR 
protein levels in LNCaP cells transfected with AR-specific siRNA 72h after transfection. TBP 
was used as a loading control. C. hTGP mRNA levels in AR knockdown LNCaP cells treated 
with 10nM R1881 or vehicle. The symbol * denotes statistical significance with respect to control 
as measured by Student-T test (p<0.05).       
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4.3.6 AR knockdown interferes with atRA-dependent hTGP expression 
The observation that AR knockdown affected hTGP expression prompted the 
question of whether AR was necessary for atRA-dependent stimulation of hTGP 
mRNA levels. For this purpose, LNCaP cells were transfected with AR-specific 
siRNA and then treated with atRA for a further 24h. hTGP expression was 
negatively affected by AR knockdown in vehicle-treated cells as reported 
previously, but it also affected atRA-dependent hTGP mRNA expression, 
decreasing its expression by around 6.5-fold (figure 19A). To compare the 
behaviour of hTGP expression to that of a known AR-target gene, PSA levels in 
AR knockdown LNCaP cells were measured. Figure 19B demonstrates that 
PSA was down-regulated by AR knockdown in both vehicle-treated and R1881-
treated cells. These results implied that AR was not regulating hTGP in the 
same way that it regulates PSA, or for that matter any other known prostate 
specific gene. To further investigate the role of the AR in hTGP expression, it 
was decided to evaluate how AR knockdown affected RAR expression. It was 
considered that if AR affected hTGP expression, it could do so indirectly by 
regulating the expression of any of the RAR, thus a down-regulation in AR 
would lead to a down-regulation in RAR expression and therefore low levels of 
hTGP expression. RAR mRNA levels in AR-knockdown LNCaP cells are shown 
in figure 19C. While RARB expression remained unaltered, RARG and RARA 
expression was increased in cells with low AR levels. 
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Figure 19.	   AR is necessary for atRA-dependent expression of hTGP. A. hTGP mRNA 
expression in LNCaP cells transfected with AR-specific siRNA and treated with 500nM atRA. B. 
PSA mRNA expression in LNCaP cells transfected with AR-specific siRNA and treated with 
500nM atRA. C. RARA, RARB and RARG mRNA expression in AR-siRNA transfected LNCaP 
cells. The symbol * denotes statistical significance with respect to control as measured by 
Student-T test (p<0.05). 
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4.3.7 AR transcriptional activity is not necessary for atRA dependent 
hTGP up-regulation 
When AR-specific siRNA was transfected into LNCaP cells, it induced a down-
regulation in AR receptor protein levels. Low levels of AR caused hTGP 
expression to be down-regulated, but whether this down-regulation was caused 
by the lack of the AR transcriptional activity or the low protein levels could not 
be distinguished. In order to investigate if the participation of the AR 
transcriptional activity was necessary for the atRA-dependent hTGP up-
regulation, LNCaP cells were treated with bicalutamide. Bicalutamide is an AR 
inhibitor that binds to the AR, allowing it to recognize and bind to AREs in the 
DNA but it prevents the recruitment of co-activators that promote transcription 
from target genes (Masiello et al. 2002). LNCaP cells were pre-treated with 5µM 
bicalutamide 12h before R1881 or atRA addition, and hTGP was evaluated 
after a further 24h. To investigate if the bicalutamide treatment was effective, 
PSA mRNA levels were measured in LNCaP cells treated with R1881 and/or 
5µM bicalutamide. Figure 20A shows that PSA mRNA levels increased in 
response to R1881 treatment, while bicalutamide and R1881 co-treatment 
resulted in almost a 50% reduction in PSA mRNA expression when compared 
to R1881 treated cells. hTGP mRNA expression in cells co-treated with 
bicalutamide and atRA remained unaltered, implying that the AR transcriptional 
activity was not necessary for atRA-dependent up-regulation of hTGP mRNA 
levels (figure 20B). 
 
Another hypothesis that could explain why AR was necessary for atRA-induced 
hTGP expression would be that atRA were directly or indirectly promoting AR 
	   111	  
shuttling into the nucleus. It has been reported that the AR does not interact 
with atRA and therefore is not activated by this compound (Fong et al. 1993). 
However, whether atRA treatment indirectly alters AR cellular localization was 
still unknown. To investigate this, an immunofluorescence assay was performed 
in LNCaP and PC346C cells to determine the AR localization after R1881 and 
atRA treatments. LNCaP and PC346C cells were grown in charcoal-stripped 
media for 24h, then treated with R1881 or atRA for 2h before cell fixation. AR 
localization in cells grown in charcoal stripped media was both nuclear and 
cytoplasmic in both LNCaP and PC346C cells (figure 21 left panels). After 
R1881 treatment, most of the AR had shuttled to the nucleus and very little 
remained in the cytoplasm (figure 21 middle panels). After atRA treatment, AR 
was not visibly re-localized to the nuclei of the cells, suggesting that atRA did 
not indirectly alter AR subcellular localization (figure 21 right panels). Thus this 
mechanism is not important in the AR regulation of atRA-dependent hTGP 
expression. 
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Figure 20. AR transcriptional activity is not necessary for atRA-induced hTGP mRNA 
expression. A. PSA mRNA expression in LNCaP cells treated with 10nM R1881, 5µM 
bicalutamide or a combination of both 24h after treatment. B. hTGP mRNA levels in 
LNCaP cells treated with 500nM atRA, 5µM bicalutamide or a combination of both for 
24h. The symbol * denotes statistical significance with respect to R1881 treated cells as 
measured by Student-T test (p<0.05). 
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Figure 21. AR subcellular localization in LNCaP and PC346C cells. A. AR subcellular localization was detected by immunofluorescence in LNCaP and 
PC346C cells treated with either 10nM R1881 or 500nM atRA for 2h. B. Controls showing immunofluorescence procedure using IgG instead of primary 
antibody and secondary antibody only. The white bar in the pictures is equivalent to 20µm. 
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4.3.8 RARG plays a major role in atRA-dependent hTGP mRNA expression 
Retinoic acid exerts most of its effects through the RARs. To confirm that atRA-
dependent regulation of hTGP expression was mediated through the RARs, 
LNCaP and PC346C cells were treated with 250 and 500nM of the synthetic 
retinoid (4-[(E)-2-(5,6,7,8-Tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-
propenyl]-benzoic acid) or TTNPB for 24h, and hTGP expression analysed by 
qPCR. This compound exclusively binds to the RARs and mediates 
transcription from their target genes (Astrom et al. 1990; Schug et al. 2007). 
Figure 22 shows that hTGP mRNA expression was up-regulated after TTNPB 
treatment in both LNCaP and PC346C cell lines. This result indicated that one 
or more of the RARs was capable of inducing hTGP upon ligand stimulation. 
Because of their importance in prostate biology, RARB and RARG were thought 
to be ideal candidates to regulate hTGP expression. RARB is expressed early 
in the rat prostate and is often found to be down-regulated in prostate cancer, 
while lack of RARG results in hyperplastic lesions in the prostate of knockout 
mice (Lohnes et al. 1995; Aboseif et al. 1997; Nakayama et al. 2001). To 
determine whether RARB and/or RARG were involved in hTGP regulation, 
LNCaP cells were transfected with RARB or RARG specific siRNAs to 
knockdown gene expression. In order to determine the best concentration of 
specific siRNA to knockdown RARB and RARG expression, LNCaP cells were 
transfected with 25 and 12.5nM of specific and scrambled siRNA. The 12.5nM 
concentration was chosen due to the effective gene knockdown and lack of 
significant alterations by the scrambled siRNA at this concentration (figure 23). 
Figure 24A and 24C show RARB and RARG knockdown at the mRNA and 
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protein level, confirming that the specific mRNAs and proteins were down-
regulated in LNCaP cells.  
 
hTGP levels in RARB knockdown cells suffered a small decrease in the 
absence of atRA treatment (figure 24B). However, when cells were treated with 
500nM atRA for 24h, there was no difference in hTGP expression between the 
mock-transfected cells, cells transfected with the scrambled siRNA and cells 
transfected with the RARB siRNA. This result implied that while RARB 
participates in hTGP basal expression, its role in atRA-dependent hTGP 
expression was nil.  
RARG knockdown also resulted in a decrease in basal hTGP expression (figure 
24D), but when RARG was knocked down in LNCaP cells with 500nM atRA 
treatment there was more than a 50% decrease in hTGP expression compared 
to hTGP expression in mock and scrambled siRNA transfected cells. These 
results therefore elucidated the importance of RARG in the atRA-dependent 
regulation of hTGP expression. 
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Figure 22. TTNPB activates hTGP expression in LNCaP and PC346C cells. The synthetic 
retinoid TTNPB, which exclusively binds to the RARs, is capable of promoting hTGP mRNA 
expression in LNCaP and PC346C cell lines 24h after treatment. The symbol * denotes 
statistical significance with respect to control as measured by Student-T test (p<0.05). 
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Figure 23.	  Selecting the best siRNA concentration to knockdown RARB and RARG expression. LNCaP cells were transfected with 25 or 12.5nM scrambled 
or specific siRNA and RARB and RARG mRNA expression was monitored at 24 and 48h. 
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Figure 24. The role of RARB and RARG in hTGP regulation. A. RARB mRNA (left) and protein (right) levels in siRNA transfected LNCaP cells 24h after 
500nM atRA or vehicle treatment for mRNA and 72h after siRNA transfection for western blot analysis. B. hTGP mRNA expression in RARB knockdown 
LNCaP cells treated with 500nM atRA or vehicle for 24h. C. RARG mRNA (left) and protein (right) levels in siRNA transfected LNCaP cells 24h after 500nM 
atRA or vehicle treatment for mRNA and 72h after siRNA transfection for western blot analysis. D. hTGP mRNA expression in RARG knockdown LNCaP cells 
treated with 500nM atRA or vehicle for 24h. The symbol * denotes statistical significance with respect to control as measured by Student-T test (p<0.05). 
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4.3.9 hTGP promoter characterization 
A previous bioinformatics analysis suggested the presence of AREs and 
RAREs in a 4.5kb section of the hTGP promoter. To test whether functional 
AREs and/or RAREs were present in the hTGP promoter, a 4.5kb section of this 
regulatory element was cloned into the luciferase reporter plasmid pGL3 basic. 
As well as the 4.5kb hTGP promoter, truncated versions of the hTGP promoter 
lacking 5’ DNA regions were cloned to investigate if loss of these regions 
resulted in lack of promoter activity (figure 25A). LNCaP cells were seeded in 
charcoal-stripped medium in 96 well-plates 24h before being co-transfected 
with the different hTGp-pGL3 promoter-reporter constructs with a normalising 
plasmid encoding the renilla luciferase gene under the control of the CMV 
promoter. 24h after transfection, cells were treated with either 500nM atRA, 
10nM R1881 or vehicle, and luciferase activity was measured after a further 
24h. Luciferase activity was normalised to the readings from LNCaP cells 
transfected with the empty vector (pGL3). Luciferase activity in cells transfected 
with the different version of the hTGP promoter showed increased activity when 
compared to the empty vector, demonstrating that all regions contained 
promoter activity. hTGP promoters between 1.5 and 3.5 kb showed the same 
luciferase activity in the absence of treatment, while the 4.5kb promoter showed 
increased luciferase expression, around 4-fold higher. This observation 
indicated the presence of a positive regulatory region located in the 5’ region of 
the hTGP 4.5kb promoter that was active in cells without stimulation (figure 
25B).  
Transfected cells treated with 500nM atRA showed a significant decrease in 
luciferase activity, except for cells transfected with the 4.5kb hTGP promoter, 
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which displayed increased luciferase activity (more than 9-fold higher than 
vehicle treated cells), implying that within the region -4500 to -3550 of the hTGP 
there is at least one active RARE (figure 25C). This result is in accordance with 
the bioinformatics analysis suggesting the presence of a RARE located at -3962. 
The fact that further deletion of the hTGP promoter had no effect on luciferase 
activity conveyed that the other RARE found in the bioinformatics analysis was 
either not active or needed the presence of the 5’ RARE or another regulatory 
sequence contained in the 5’ region of the 4.5kb hTGP promoter for hTGP 
regulation. 
R1881 treatment resulted in a decrease in luciferase activity only in those cells 
transfected with the 4.5kb hTGP promoter (around 40% reduction in luciferase 
activity), while no significant changes were seen in cells transfected with other 
constructs (as shown in figure 25D).  
Taken together, these results indicated the presence of an active RARE and 
ARE in a 1kb region at the 5’ of the 4.5kb hTGP promoter. Given that this 
region is not directly adjacent to the transcription start site of the gene and that 
there appeared to be no further important elements between this region and the 
minimal hTGP promoter, it is proposed that this region contains an enhancer 
regulated by both retinoic acid and androgen. 
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Figure 25.	   hTGP promoter analysis. A. Schematic representation of the hTGP regions, 
containing responsive elements cloned into the luciferase vector pGL3 basic. B, C and D. 
Relative luciferase activity in LNCaP cells co-transfected with different constructs containing the 
4.5kb hTGP and several deletion mutant versions and the normalising plasmid CMV-pRL. 
Luciferase activity was measured 24h after transfection (B), 24h after 500nM atRA treatment, 
48h after transfection (C), or 24h after 10nM R1881 treatment, 48h after transfection (D). The 
symbol * denotes statistical significance with respect to control as measured by Student-T test 
(p<0.05). 
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4.3.10 Mapping the direct binding of AR and RAR to the hTGP promoter 
To complete the analysis of the hTGP promoter, it was decided to map the 
binding sites of the AR and RAR to this regulatory region. In order to do so, 
vehicle, atRA and R1881 treated LNCaP cells were subjected to chromatin 
immunoprecipitation (ChIP). LNCaP cells were grown in T150 flasks in charcoal 
stripped media for 24h, then treated with vehicle, 500nM atRA or 10nM R1881 
for 10h. Following treatment, cells were fixed using paraformaldehyde, to 
promote the cross-linking of proteins and DNA, chromatin was extracted and 
sonicated to produce short-length DNA fragments. DNA-bound AR and RAR 
was immunoprecipitated using specific antibodies, and DNA purified by phenol-
chloroform extraction. DNA fragments were amplified by qPCR using specific 
primers spanning the hTGP promoter in regions where either AR/RAR binding 
was expected (regions AB, B and NO), and in regions where receptor binding 
was not expected (regions 4, 5, N and M) as shown in figure 26A. RAR binding 
to the hTGP promoter in vehicle-treated cells was higher at regions -3745, -
1647 and -1504, which are close to or within RAREs located at -3962 and -1647 
(figure 26A and B). It was expected to find RAR binding to the DNA in the 
absence of ligand since the current model (Chambon 1996) suggests that 
RARs are able to bind to the DNA in the absence of ligand, while ligand binding 
promotes the recruitment of co-activators to the regulatory region to promote 
gene transcription. AR binding to the hTGP promoter in vehicle-treated cells 
matched the binding sites of the RAR in the same region, but tended to be 
lower than RAR binding across the hTGP promoter (figure 26C).  
RAR binding to the hTGP promoter in atRA-treated LNCaP cells remained very 
similar to the pattern shown in vehicle treated cells. Interestingly, AR binding 
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across the hTGP promoter in atRA-treated LNCaP cells showed a uniform 
decrease showing similar levels as for the IgG control, except at the -3962 
region where it remained constant (figure 26C). Since AR is necessary for 
complete hTGP mRNA expression following atRA treatment, it is noteworthy 
that the only region where AR binding remained unaltered is adjacent to the 
RAR binding site. This implied that AR binding in the -3962 region was 
important in the atRA-dependent hTGP expression, opening the possibility that 
the AR and the RAR might interact in the regulation of hTGP. 
R1881 treatment in LNCaP cells caused a decrease in RAR binding to the 
hTGP promoter (figure 26D) but also a significant increase in AR binding to the 
-3962 region. Since R1881 treatment stimulated AR binding to the hTGP 
promoter, it is tempting to hypothesize that androgen-bound AR actively 
represses hTGP either by recruiting co-repressors or by impeding the RAR 
activity. Whether RAR discharge off the hTGP was caused by steric impediment 
or any other mechanism remains to be investigated. A proposed model for 
hTGP regulation, summarising the findings of this work is depicted in figure 27. 
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Figure 26. AR and RAR binding to the hTGP promoter. A. AREs, RAREs and primer amplifying regions for ChIP-qPCR analysis of the hTGP promoter. B. AR and RAR 
binding to the hTGP plotted as percentage of input (left) and relative binding (right) LNCaP cells treated with vehicle for 10h. C. AR and RAR binding to the hTGP plotted 
as percentage of input (left) and relative binding (right) LNCaP cells treated with 500nM atRA for 10h. D. AR and RAR binding to the hTGP plotted as percentage of input 
(left) and relative binding (right) LNCaP cells treated with 10nM R1881 for 10h. The symbol * denotes statistical significance with respect to IgG control as measured by 
Student-T test (p<0.05). 
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Figure 27. Proposed mechanism of hTGP regulation by retinoic acid and androgen. A. In an 
environment where retinoic acid and androgen concentrations are low, the AR and RAR are 
bound to the hTGP promoter allowing basal transcription. B. Retinoic acid-bound RAR activates 
transcription, with the help of the AR, most likely by recruiting co-activators to the hTGP 
promoter. C and D. Androgen-bound AR increases its binding to the hTGP promoter, actively 
repressing hTGP expression either by the recruitment of co-repressors or impeding the 
recruitment of co-activators and/or factors that allow hTGP expression. 
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4.4 Testing the baculovirus-hTGP-NTR in prostate cancer cell lines 
4.4.1 Utility of the hTGP promoter in prostate cancer gene therapy 
In order to test whether the NTR enzyme used to cause targeted cell death 
following CB1954 treatment could be expressed using the hTGP promoter as a 
regulatory sequence, NTR was cloned in place of luciferase in the hTGP 4.5kb-
pGL3 plasmid, now re-named hTGP4.5-NTR. 
LNCaP cells were grown in charcoal-stripped medium for 24h, then transfected 
with hTGP4.5-NTR plasmid. Cells were then treated with vehicle or 500nM 
atRA 24h after transfection, and NTR expression was measured by western blot 
analysis, 24h and 48h after vehicle or atRA treatment. Figure 28 shows that 
NTR expression could be detected only in cells transfected with the hTGP4.5-
NTR plasmid that had also been treated with atRA. NTR expression was 
sustained at 24h and 48h following atRA treatment. When the NTR levels of the 
positive control, LNCaP cells transfected with the CMV-NTR plasmid, were 
compared to those of cells transfected with the hTGP4.5-NTR plasmid and 
treated with atRA using semi-quantitative densitometry, a 10-fold difference was 
observed between samples, indicating that while the hTGP promoter could be 
helpful for prostate targeting, it was also less strong than CMV in producing 
NTR enzyme (figure 28B). 
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Figure 28. The hTGP promoter activates NTR transcription following atRA treatment. A. 
Western blot analysis showing NTR expression in transfected LNCaP cells, transfected with 
hTGP4.5-NTR and treated with either 500nM atRA or vehicle for 24h or 48h. β-actin was used 
as loading control. B. NTR expression as analysed by semi-quantitative densitometry. NTR 
expression was normalised to β-actin expression. The positive control consisted in whole 
protein extracts from LNCaP cells transiently transfected with a construct containing the NTR 
gene under the control of the CMV promoter. 
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4.4.2 hTGP promoter activity in prostate and non-prostate cell lines 
LNCaP, PC3, PNT1A (prostate cell lines) and HeLa, MCF7 and T47D (non-
prostate cell lines) were grown in complete medium and transfected with 
hTGP4.5-Luc plasmid and treated with 500nM atRA to assess the activity of the 
hTGP promoter in prostate and non-prostate cell lines. Figure 29A illustrates the 
firefly and Renilla luciferase activities in each cell treated either with vehicle or 
atRA. Firefly and Renilla luciferase readings are a reflection of promoter activity 
and transfection efficiency. Transfection efficiency was measured by Renilla 
luciferase readings. Since the early CMV promoter controls the expression of 
Renilla luciferase, it was expected to obtain similar Renilla luciferase activities in 
the different prostate and non-prostate cell lines. However Renilla expression 
varied from cell line to cell line by orders of 10- to more than 100-fold (figure 
29A). This phenomenon could be explained by the differential ability of the 
transfection reagent to deliver plasmid DNA into different cell lines and the 
dissimilar activity of the CMV promoter in diverse cellular contexts (Cheng et al. 
1993). Therefore, to compare the hTGP promoter activity in different cell lines, it 
would be necessary to either use a transfection method that can deliver plasmid 
DNA into all the different cell lines with exactly the same efficiency and/or a 
normalizing plasmid where the expression of Renilla luciferase was controlled 
by a promoter equally strong in all cell lines. To compare the hTGP promoter 
between different cell lines, the activity of each cell line transfected and treated 
with atRA was normalised to the activity of the same cell line transfected and 
treated with vehicle (figure 29B). Luciferase expression was enhanced by atRA 
treatment only in LNCaP cells. Not even PC3 or PNT1A cells showed an 
increase in luciferase expression following atRA treatment. This could be 
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related to the differentiation status of the prostate cell lines. While LNCaP 
represent a more differentiated cell type, PC3 and PNT1A have phenotypical 
characteristics of less differentiated cells. hTGP expression has been found to 
be restricted to the highly differentiated luminal cells in prostate (Dubbink et al. 
1999b), suggesting that expression in less differentiated cell types is 
suppressed. Part of the suppression mechanism could rely on the promoter 
sequence and therefore PC3 and PNT1A cells were unable to up-regulate 
luciferase expression in response to atRA treatment. HeLa, MCF7 and T47D 
cells also failed to up-regulate luciferase expression under the control of the 
hTGP, following atRA treatment. Interestingly, although MCF7 cells are known 
to express RARs and AR (Ross-Innes et al. 2010; Subik et al. 2010), key 
transcription factors in hTGP regulation, no significant change was observed 
after atRA treatment. Whether the 4.5kb hTGP promoter contains enough 
information to express genes in a prostate specific manner requires further 
investigation. 
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Figure 29. hTGP promoter activity in prostate and non-prostate cell lines. A. Luciferase activity 
of hTGP4.5-Luc transfected and atRA treated cells measured in arbitrary luminescence units. 
The CMV promoter controlled Renilla luciferase expression. B. Relative luciferase expression of 
hTGP4.5-Luc transfected and atRA treated cell lines normalised to vehicle treated samples. The 
symbol * denotes statistical significance with respect to vehicle control as measured by Student-
T test (p<0.05). 
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4.4.3 NTR half-life in LNCaP cells 
NTR half-life in human cells is unknown. Since in this study it was intended to 
induce NTR expression using the hTGP promoter, that is weaker in comparison 
to the CMV promoter, it was necessary to measure NTR half-life to assess 
whether this would be a potential issue. For this purpose, LNCaP cells were 
transfected with the hTGP4.5-NTR plasmid and treated with 500nM atRA for 
24h. Following atRA treatment, cells were treated with 5µM cycloheximide, a 
drug that halts protein synthesis, and cells were harvested at various time 
points ranging from 2-10h. Samples were analysed by western blot, using as a 
comparison, a protein with a well-characterized half-life in prostate cells, 
clusterin (Rizzi et al. 2009). Figure 30A shows that protein levels of clusterin, 
decreased over time, and were practically undetectable 10h after cycloheximide 
treatment. NTR appeared to be more stable, showing detectable levels 10h 
following cycloheximide treatment. Semi-quantitative densitometry measuring 
clusterin and NTR decay over time indicated a half-life of 2h for clusterin and 
10h for NTR (figure 30B). Clusterin is considered as an unstable protein, given 
its rapid degradation. However, NTR was around 5 times more stable, indicating 
that NTR half-life would not be an issue in NTR/CB1954 treatments. This also 
implies that a very strong promoter is not necessarily needed and a weak 
promoter could also be of use to express NTR. 
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Figure 30. NTR half-life in human prostate cells. A. Western blot analysis of clusterin, NTR and 
β-actin of LNCaP cells transfected with hTGP4.5-NTR plasmid, treated with 500nM atRA to 
induce NTR expression, followed by a cyclohexamide treatment to inhibit protein synthesis and 
harvested between 2-10h. B. Semi-quantitative densitometry evaluating clusterin and NTR 
decay over time. 
0	  20	  
40	  60	  
80	  100	  
0	   2	   4	   6	   8	   10	   12	  %	  of
	  o
	  s
ta
rt
in
g	  
pr
ot
ei
n	  
Time	  (h)	  
Clusterin	  
0	  20	  
40	  60	  
80	  100	  
0	   2	   4	   6	   8	   10	   12	  %	  o
f	  s
ta
rt
in
g	  
pr
ot
ei
n	  
Time	  (h)	  
NTR	  
A	  
B	  
	   136	  
4.4.4 Building the hTGP4.5-NTR baculovirus 
A recombinant baculovirus encoding the NTR gene under the control of the 
hTGP promoter was engineered using the Bac-toBac baculovirus expression 
system. The hTGP promoter and NTR sequences were cloned into the 
recombinant donor plasmid pFASTBac1. Cloning into this plasmid results in the 
cloned sequences being flanked by the donor Tn7L and Tn7R sequences to 
allow site-specific recombination. To confirm the correct cloning and 
functionality of the hTGP and NTR genes, plasmids were sequenced and two of 
those that contained the correct sequence were transfected into LNCaP cells 
that were further treated with 500nM atRA. Cells were lysed and total protein 
extracted and analysed by western blot. Figure 31B shows that both plasmids 
produce NTR expression following atRA treatment, while untreated cells 
displayed no visible levels of NTR in accordance with previous results. The 
hTGP4.5-NTR pFASTbac1 plasmid was then transformed into competent 
DH10Bac E. coli cells. These cells contain a recombinant baculovirus genome 
where a LacZ gene contained, within its sequence, the acceptor Tn7L and 
Tn7R sites. Successful site-directed recombination resulted in LacZ disruption 
and failure to produce blue colonies when bacteria were grown in the presence 
of IPTG and X-gal. Ten white colonies were tested for the presence of the 
hTGP promoter and NTR sequences by isolating the baculovirus genome and 
amplifying a section of it by PCR, using specific primers that flanked both 
human DNA sequences and should produce a 9kb product. Two baculovirus 
genomes from different colonies that showed presence of hTGP and NTR 
sequences were transfected into sf9 insect cells to initiate production of 
baculovirus particles. 96h after infection, supernatant was collected and stored 
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for further amplification. Before amplification of a baculovirus, its viral DNA was 
tested by PCR to verify whether it contained the hTGP promoter and NTR 
sequences using two sets of primers. The first one flanked both hTGP and NTR 
sequences, yielding a 9kb amplification product and was used to identify 
baculovirus genomes that contained the insert. The second set of primers was 
localized within the hTGP promoter and the NTR gene sequences and amplified 
a region of around 4.5 kb. Both baculovirus genomes isolated from viral 
particles showed the presence of hTGP and NTR sequences assuring the 
correct construction of the virus (figure 31C and 31D). 
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Figure 31. Engineering a prostate targeted baculovirus for gene therapy. A. Overview of the procedure to build the hTGP4.5-NTR baculovirus, taken from the Bac to Bac 
manual (4th September 2010, Invitrogen. The hTGP-NTR sequences were cloned into the pFASTBac1 vector. hTGP4.5-NTR pFASTBac1 was transformed into DH10Bac 
cells to promote site-specific recombination into the baculovirus genome. Baculovirus genome was isolated and transfected into sf9 insect cells to produce baculovirus 
particles. B. Western blot analysis of NTR expression in LNCaP cells transfected with the plasmid hTGP4.5-NTR pFASTBac1 and treated with 500nM atRA or vehicle for 
24h. C. PCR analysis of the presence of hTGP promoter and NTR gene sequences in purified baculovirus genomes from bacterial colonies. Lanes 1-6 are baculovirus 
genomes from different colonies; lane 7 is the negative control. D. PCR analysis of the baculovirus genome extracted from viral particles generated by two different 
parental genomes. Lanes 1 and 3 were amplified using specific primers that flank the hTGP and NTR sequences in the Baculovirus genome. Lanes 2 and 4 were amplified 
using primers that amplified a sequence within the hTGP promoter and the NTR gene. Lane 5 is the negative control. 
C	   D	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4.4.5 Testing the ability of the baculovirus to infect non-prostate cell lines 
Before testing the ability of the hTGP4.5-NTR baculovirus to induce cell death, it 
was decided to test the baculovirus’ ability to transduce non-prostate cell lines. 
It was of particular importance to perform this experiment in order to be able to 
discern the cell specificity of the hTGP promoter and the overall efficiency of the 
cells to be transduced by the virus. MCF7, T47D and HeLa cells were 
transduced with BV-EGFP using LNCaP cells as a positive control to test the 
susceptibility of each non-prostate cell line to be transduced by baculovirus. 
Figure 32 shows that non-prostate cell lines are very poorly susceptible for 
baculovirus transduction, when compared to LNCaP cells. Non-prostate cell 
lines showed less than 2% EGFP-expressing cells; in comparison to 68% EGFP 
expressing LNCaP cells. These results should be interpreted carefully, since the 
baculovirus used for this experiment used the CMV promoter as the regulatory 
element to control EGFP expression. As mentioned before, CMV has been 
shown to have different activity depending on the cell type context. Therefore, 
to measure to which degree EGFP expression was a measure of successful 
transduction without being affected by promoter activity, more experiments 
featuring baculoviruses expressing EGFP from different promoters are needed. 
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Figure 32. Non-prostate cell lines susceptibility to baculovirus transduction. MCF7, T47D and 
HeLa cells were transduced with the recombinant baculovirus BV-EGFP for 2h. 24h following 
transduction cells were harvested, washed and re-suspended in PBS. Percentage of EGFP 
positive cells was measured by FACS analysis. LNCaP cells were used as a positive control. 
0% 61% 
1000	  MOI 
LNCaP 
MCF7 
0% 1.88% 
0% 0.44% 
T47D 
0% 1.7% 
HeLa 
Untransduced 
	   142	  
4.4.6 hTGP4.5-NTR baculovirus ability to cause cell death in LNCaP cells 
LNCaP cells were transduced with the hTGP4.5-NTR baculovirus to test 
whether treating them with CB1954 could kill transduced cells. Cells were 
incubated with recombinant baculovirus for 4h at RT, then at 37°C for 24h. 
Transduced cells were treated with 500nM atRA (to stimulate NTR expression) 
or vehicle for 24h before CB1954 addition. As controls, untransduced cells were 
treated with vehicle, atRA, CB1954 or a combination. 72h after CB1954 
treatment, cell viability was measured by MTS assay. Cells transduced with the 
hTGP4.5-NTR baculovirus and treated with CB1954 displayed a reduction in 
cell viability of 37%, around the reduction observed when cells were pre-treated 
with atRA (figure 33A), meaning that atRA treatment did not enhance cell death. 
Interestingly, cells transduced with the hTGP4.5-NTR baculovirus, but not 
treated with CB1954, also showed a decrease of 28.7%, suggesting that the 
virus on its own causes some degree of cell cytotoxicity.  
 
To investigate why atRA pre-treatment did not enhance cell death following 
CB1954 exposure, LNCaP cells were transduced and treated with atRA or 
vehicle. Cells were harvested 24h following atRA treatment and protein was 
extracted to analyse NTR expression by western blot analysis. Figure 33B 
demonstrates that NTR expression in transduced LNCaP cells was 
undetectable, even after atRA treatment. This is most likely caused by the 
sequences surrounding the hTGP promoter, as it has been inserted in the 
baculovirus genome, since the virus used to transduce LNCaP cells was proved 
to have the hTGP promoter and NTR sequences intact. Therefore, gene 
expression was altered in the context of the viral genome in contrast to plasmid 
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alone. While further experiments, including the evaluation of NTR mRNA 
expression in baculovirus transduced cells and baculovirus genome transfection 
into mammalian cells, are needed to clarify at which step NTR expression is 
prevented, the findings of this work have taken baculovirus-based prostate 
cancer gene therapy a step forward. We have proved the value of the 
NTR/CB1954 system and baculovirus for its use not only in prostate cell lines 
but also in prostate epithelial primary cultures. By investigating the regulation of 
the hTGP promoter we have discovered a new interaction between AR and 
RAR that is actively regulating a highly prostate specific gene. These findings 
provide encouraging evidence of the  potential use of our system for prostate 
cancer gene therapy. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	   144	  
Figure 33. Activity of the hTGP4.5-NTR baculovirus in LNCaP cells. A. Percentage of viable 
cells transduced with the hTGP4.5-NTR baculovirus, treated with either 500nM atRA or vehicle 
for 24h, then treated with 20µM CB1954 or vehicle for 72h. Cell viability was measured by MTS 
assay. B. NTR protein expression in LNCaP cells transduced with hTGP4.5-NTR baculovirus 
and treated with 500nM atRA or vehicle for 24h. As a positive control cells were transfected with 
the hTGP4.5-NTR plasmid and treated with 500nM atRA (lane 2). 
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5.	  DISCUSSION	  
 
5.1 The role of RARs and AR in the prostate 
The amount of research in the role of RARs and AR in prostate function and 
homeostasis is highly dissimilar. Although previous studies suggest a major role 
for retinoic acid and RARs in prostate homeostasis, a detailed examination of 
the mechanism of action remains understudied. It has been shown that the 
retinoic acid pathway and RARs expression are both enhanced in primitive 
murine prostate epithelial cells. Aldehyde dehydrogenase genes, which 
catalyse the transformation of retinol into retinoic acid, were shown to be up-
regulated in the urogenital epithelial sinus, and in both foetal and adult prostate 
stem cell populations. Rxra, Rarb and Rarg have also been shown to be highly 
expressed in adult and foetal stem cells (Blum et al. 2009). This data suggested 
that retinoic acid signalling is important during prostate development, but also in 
adult prostate, and could play a role in the regulation of prostate stem cells. 
 
Perhaps the most studied role of retinoic acid and RARs in prostate is its link to 
cancer development. RARB hypermetylation seems to be a common feature of 
malignant prostate cells in the majority of the patients (Vasiljevic et al. 2011). 
Retinoic acid treatment can cause apoptosis in prostate cancer cell lines PC3 
and DU145, through up-regulation of the TNFRSF12A, TNFRSF1A and 
TNFRSF10B genes (Karabulut et al. 2011). Retinoic acid has also been used to 
enhance cell death in castration-resistant prostate cells subject to suicide gene 
therapy (Chen et al. 2008). While the means of protection against prostate 
cancer development conferred by retinoic acid remains unknown, research in 
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other cancer types reveals important mechanisms that could play a role in 
prostate cancer. Retinoic acid induces the expression of G0S2, TNFAIP2, 
SMAD3, and NRIP1 by RAR binding to the promoter of these genes in 
endometrial cells. Up-regulation of these genes could result in cell cycle arrest, 
apoptosis and reduced motility, features that are also increased when the cells 
were treated with retinoic acid (Cheng et al. 2011). 
 
On the other hand, the role of AR in prostate homeostasis and prostate cancer 
has been investigated in some detail. Among the most exciting recent findings 
is the AR interaction with the transcription factor FOXA1. This regulatory 
mechanism has uncovered a new layer of complexity in AR activity. FOXA1 is 
able to both induce and prevent AR binding to a subset of AREs in the genome. 
Lack of FOXA1 expression results in an aberrant gene expression profile, that 
could lead to, or be a further step towards, prostate cancer development (Sahu 
et al. 2011). Interestingly, AR’s role in prostate homeostasis is not restricted to 
growth and survival. AR targets include genes involved in metabolic processes. 
GLUT1, HK1/2 and PFKFB2, genes involved in glucose uptake and glycolysis, 
and FASN/ACACA, genes playing a role in biosynthetic processes, are all 
genes up-regulated by androgen exposure, and are likely to contribute to 
prostate cancer by providing the raw materials and means for the cancer cells 
to maintain their growth (Massie et al. 2011). 
These recent studies emphasise two key findings regarding AR activity. First, 
they stress the importance of the interaction of AR with other transcription 
factors and second, they highlight the notion that the activity of the AR is not 
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just to provide survival signals, but to help the cells grow by stimulating 
metabolic machinery. 
 
The findings in the present work demonstrate that retinoic acid and RARs have 
an opposite effect on the regulation of the hTGP gene in comparison to 
treatment with androgens. It was also found that AR knockdown resulted in 
RARA and RARG mRNA up-regulation, and that retinoic acid treatment yielded 
low AR binding to the hTGP promoter. All these observations, of opposing 
effects between androgen and retinoic acid, suggest that one of the roles of 
retinoic acid in prostate homeostasis could be to counteract or moderate the 
effects of androgen.  
 
Similar observations of the opposing effect of androgen and retinoic acid had 
been made in the past. In the AR-expressing breast cancer cell line T47D, 
retinoic acid treatment results in AR down-regulation of expression and activity 
(Hall et al. 1992). Moreover, retinoic acid treatment of LNCaP cells resulted in 
reduced AR binding activity, and repression of KLK3 and KLK2 expression, 
both prostate-specific and androgen regulated genes, in a dose dependent 
manner (Young et al. 1994). The effect of retinoic acid on LNCaP cells was 
however dependent on the presence of androgens. While retinoic acid 
treatment alone stimulated growth and differentiation, a combined treatment 
with androgens yielded growth inhibition (Esquenet et al. 1996), suggesting that 
the combined treatment promotes an interaction of the stimulated mechanisms 
triggered by these hormones. It is known that retinoic acid can have contrasting 
effects on proliferation and cell survival depending on the cell type. The effect of 
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retinoic acid on survival and growth appears to be determined by the 
expression of the retinoic acid binding proteins CRABP-II and FABP5. Retinoic 
acid induces cell death and proliferation arrest in cells that express high levels 
of CRABP-II and low levels of FABP5, mainly through the activity of the RARs. 
Induction of proliferation and survival is triggered by retinoic acid in cells with 
high FABP5 levels by inducing the activation of the PPARB/D (peroxisome 
proliferator-activated receptor beta/delta) (Schug et al. 2007). Therefore it would 
be interesting to investigate whether androgens stimulate or repress the 
expression of either CRABP-II or FABP5, which should result in the modulation 
of the response to retinoic acid, and explain the differential response to retinoic 
acid in the presence/absence of androgen. 
When retinoic acid treatment induces cell death, Rb activation and down-
regulation of AR protein expression precedes the activation of apoptosis in 
LNCaP cells (Gao et al. 1999), suggesting that retinoic acid could also be able 
to modulate the AR activity. 
 
Another nuclear steroid receptor with an opposing role to the RAR, in breast 
cancer cells, is the oestrogen receptor (ER). Similarly to its effect on prostate 
cells, retinoic acid induces apoptosis and proliferation arrest in breast cancer 
cells, while oestrogen induces cell proliferation and survival. In MCF7 cells, 
RAR and ER binding sites have a high co-localization rate of 39.3% (within 1kb 
distance between binding sites) and the shared number of genes that they bind 
to is 59.8%. RAR and ER therefore compete to bind to overlapping sites, and 
the activation of one down-regulates the activity of the other (Hua et al. 2009). 
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However RAR and ER can also interact and cooperate to induce transcription of 
genes. It has been shown that the RARA can bind to oestrogen responsive 
elements (EREs) and that this binding depends on the presence of the ER and 
oestrogen (Ross-Innes et al. 2010). RARA interaction with the ER control the 
expression of about a third of all ER regulated genes. The mechanism of this 
interaction seems to rely on the ability of the RARA to facilitate ER/co-activator 
interactions (Ross-Innes et al. 2010). Presence of the RARA ligand, retinoic 
acid disrupts the cooperation between the nuclear receptors and favours the 
transcription or RARA regulated genes (Ross-Innes et al. 2010). 
 
These studies clearly suggest an antagonistic role of retinoic acid to that of 
androgen regarding cell survival and growth in prostate cells. They also suggest 
that RARs can oppose the proliferative and survival effects of another steroid 
hormone, oestrogen, in breast cells. The findings in this work are not only in line 
with these previous reports, but provide a putative mechanism for the regulation 
of this antagonistic relationship. It was found that AR played a dual role in the 
regulation of hTGP expression. In the presence of atRA, AR cooperated with 
the RARG to induce hTGP expression, while the presence of androgen caused 
increased AR binding to the hTGP promoter that resulted in transcriptional 
repression.  
It will be interesting to research if the regulatory circuit controlling hTGP 
expression can be found in more genes, a very likely event, but it may be more 
important to identify the roles of such genes, and to evaluate how their 
differential expression impacts on prostate function and homeostasis. 
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5.2 Prostate-specific expression 
The role of AR in prostate-specific gene expression is widely acknowledged. 
Tissue-specific expression is regulated mainly through enhancers and the 
prostate is no exception. It has been recently described how FOXA1, a 
transcription factor highly expressed in the prostate, interacts with the AR to 
facilitate and restrict its binding to active enhancer elements, consequently 
regulating the expression of target genes (Wang et al. 2011). 
The discovery of transcription factors, apart from AR, modulating the expression 
of prostate-specific genes, questions the assumed solitary role of AR in 
prostate-specific gene expression. KLK3 (or PSA) is probably the most studied 
prostate specific gene. It is widely used as a cancer biomarker and is known to 
be regulated by the action of androgens through the androgen receptor 
(Andreu-Vieyra et al. 2011). However, PSA is not solely regulated by the action 
of androgens. It was recently demonstrated that treating LNCaP cells with the 
cytokine IL-6 could induce PSA expression. The IL-6-dependent increase in 
PSA expression was mediated by the signal transducer and activator of the 
transcription 3 (STAT3), the heat-schock protein 90 (HSP90) and a previously 
described androgen enhancer region (Tsui et al. 2011).  
 
FOLH1 is the best example of a prostate specific gene whose expression is 
down-regulated by the effects of androgen. As with most prostate specific 
genes, FOLH1 expression is regulated by an enhancer located in the third 
intron of the gene. This enhancer mediates, alongside the FOLH1 promoter, the 
androgen-dependent repression observed in prostate cells (Noss et al. 2002). 
One of the key transcription factors that bind to the FOLH1 enhancer is AP-3. 
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Site directed mutagenesis which caused a DNA sequence change in the AP-3 
binding site, triggered the repression of the enhancer’s activity. Also bound to 
this enhancer was the transcription factor NFATc1, suggesting a possible 
cooperation with AP-3 to induce FOLH1 expression (Lee et al. 2003). Recently 
described is the involvement of ERG and the TMPRSS2-ERG fusion in the 
regulation of FOLH1 expression. It was found that expression of the TMPRSS2-
ERG fusion could inhibit FOLH1 expression. Since in this fusion the regulatory 
region, and some of the first exons of the TMPRSS2 gene, are fused to a 
section of the ERG gene, it is probable that androgen induction of this fusion is 
responsible for the down-regulation in FOLH1 expression. Interestingly, ERG 
siRNA knockdown resulted in increased FOLH1 expression, suggesting that it is 
ERG which is the factor controlling FOLH1 expression, since this effect could be 
observed in the presence of androgen (Yin et al. 2011). 
 
NKX3.1 is another prostate-specific gene, which is regulated by multiple 
transcription factors. AR regulates NKX3.1 expression by binding to an 
enhancer at the 3’ UTR of the gene that contains AREs (Thomas et al. 2010). 
The transcription factor ETS1 is also able to modulate NKX3.1 by binding to the 
gene’s proximal promoter (Preece et al. 2011). ERG and ESE3, another ETS 
transcription factor, have been shown to regulate the expression of NKX3.1 
through the induction of EZH2 (Kunderfranco et al. 2010). More interestingly 
perhaps is the observation that retinoic acid is also able to directly up-regulate 
NKX3.1 protein expression and transcription in LNCaP prostate cancer cells 
(Thomas et al. 2006). 
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In the present study it is described how retinoic acid drives the expression of 
the highly prostate specific gene hTGP, through the activation of the RARG. 
This is, up to date, only the second example of a prostate specific gene 
regulated by retinoic acid. It becomes clearer that the idea of AR and androgen 
as solitary regulators of prostate-specific expression needs to change to favour 
a more complex and realistic interplay between a plethora of different 
transcription factors. This will allow investigators to gain an insight into the 
complex control of tissue-specific expression that could lead to breakthroughs 
in many areas of science and medicine including gene and stem cell-based 
regeneration therapies. 
 
5.3 Baculoviruses in gene therapy 
Most of the vectors used for gene therapy purposes are viruses that naturally 
infect human cells and tissues. One of the advantages of using these viruses is 
that they possess specific means to infect human cells and therefore are highly 
efficient at delivering desired transgenes. However, since these are natural 
pathogens, the human body is prepared to sustain a rapid and efficient immune 
response upon detection of these parasites. This immune response poses the 
major obstacle in using human-infecting viruses for gene therapy, since the total 
amount of virus that can be applied to a subject is limited in quantity and in 
number of doses.  
Baculovirus offers an alternative to these problems, featuring high transduction 
efficiency in vertebrate and mammalian cells (Airenne et al. 2011), while being 
unable to induce memory immune responses from human hosts. Research 
using baculovirus as a vector for gene therapy has increased recently. Neural 
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stem cells (NSC) with tropism for tumours were infected with a recombinant 
baculovirus encoding the herpes simplex virus thymidine kinase gene. 
Baculovirus-transduced NSC showed thymidine kinase expression for as long 
as three weeks, and injection of transduced NSC followed by gancyclovir 
treatment into mice growing human glioma xenografts resulted in inhibition of 
growth and prolonged survival (Zhao et al. 2011).  
Another baculovirus-based effort to treat glioma took advantage of the 
observation that sodium butyrate (NaBu) enhanced baculovirus transduction 
efficiency. The human glioma cell line U251 were transduced with a 
recombinant baculovirus armed with the WT p53 gene, to induce apoptosis, in 
combination with NaBu treatment. By combining NaBu with baculovirus 
transduction, p53 expression was improved, resulting in enhanced cell death 
rates. In vivo efficacy was corroborated by intratumoral injection of recombinant 
baculovirus alongside NaBu treatment of U251 tumours growing in nude mice. 
Baculovirus/NaBu treated tumours showed decreased proliferation (Guo et al. 
2011). 
 
The need for tumours to increase blood vessel formation to sustain their growth 
has also been targeted by gene therapy using baculovirus vectors. A 
recombinant baculovirus capable of expressing the fusion protein hEA, a fusion 
between human endostatin and angiostatin with anti-angiogenic activity has 
been shown to have anti-proliferative and anti-angiogenic potential. When 
injected intratumorally, in prostate cancer mouse xenografts, the recombinant 
baculovirus inhibited tumour growth and prolonged host survival, in comparison 
to the controls (Luo et al. 2011b). 
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One of the downsides of using baculoviruses is that gene expression is 
transient. Trying to confer stable expression a recombinant baculovirus 
expressing the sleeping beauty (SB) transposase and containing the hEA gene, 
flanked by inverted repeat/direct-repeat (IR/DR) elements recognized by the SB 
transposase, was built. This hybrid baculovirus showed increased duration of 
transgene expression when compared to traditional baculoviruses, affecting 
both tumour growth and prolonging survival in prostate and ovarian cancer 
allograft mice models (Luo et al. 2011a). 
 
The use of baculovirus as a vector for prostate cancer gene therapy is 
investigated in prostate cancer cell lines in this work. The findings presented 
here suggest that, as observed by many other groups in the world, 
baculoviruses are capable of transducing human cancer cells with high 
efficiency. It was also found in this research that baculoviruses have a 
“preference” to transduce prostate cancer cell lines rather than normal prostate 
cell lines, cervical cancer or breast cancer cell lines. Expanding the research of 
which cell types can be transduced by baculoviruses will not only expand its 
use into permissive tissues but also will provide valuable information of which 
de-targeting strategies are required to prevent undesired gene expression in 
off-target tissues. 
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5.4 The NTR/CB1954 system 
Suicide gene therapy is an attractive option to cause cell death among cancer 
cells. It confers the advantage of requiring to be expressed only by a fraction of 
a given population in order to induce widespread cell death by a mechanism 
denominated bystander effect. It is this particular characteristic that places the 
NTR/CB1954 system apart from the other suicide gene therapy methods. The 
NTR gene has been modified to adapt it to the mammalian codon usage. These 
changes resulted in enhanced expression, sensitivity to CB1954 and increased 
bystander effect (Grohmann et al. 2009). A clinical trial using a replication-
defective adenovirus armed with the NTR gene was administered via 
intraprostatic injection and NTR expression could be found in the majority of the 
patients (Patel et al. 2009). 
An interesting approach to induce NTR expression in cancer cells is to make 
use of hypoxia-responsive elements (HREs) to regulate the expression of NTR. 
By using a regulatory region comprised of the minimal CMV promoter linked to 
HREs from VEGF and erythropoietin, NTR expression could be targeted to 
tumour-hypoxic regions. This resulted in inhibition of tumour growth following 
prodrug administration (Harvey et al. 2011). 
Another feature common to most tumours is the expression of human 
telomerase reverse transcriptase (hTERT). Using an hTERT regulatory region 
to control the expression of NTR and Herpes Simplex virus thymidine kinase 
(HSV-TK) coupled to gancyclovir and CB1954 treatment has been used as a 
combinatorial GDEPT treatment. A bicistronic adenovirus coding the HSV-TK 
and NTR genes separated by an IRES sequence and regulated by the hTERT 
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promoter showed higher anti-tumoural activity than single HSV-TK or NTR 
adenovirueses in breast cancer human cells (Yu et al. 2011). 
In this study we have proved that NTR/CB1954 combination can efficiently kill 
prostate cancer cells. The use of the humanized NTR and a combination of 
different GDEPT enzymes is an exciting prospect for prostate cancer gene 
therapy. 
 
5.5 Current gene therapy for prostate cancer 
Gene therapy has shifted from being a futuristic approach, to a treatment that 
needs fine-tuning before reaching the bedside. One of the most used 
approaches for prostate cancer gene therapy is the utilization of oncolytic 
viruses. These viruses have the ability to replicate in cancer cells only due to 
the use of cancer-specific or in some cases tissue-specific promoters, 
regulating the expression of genes necessary for viral replication. One of the 
most exciting prospects for oncolytic gene therapy has been recently described. 
The approach uses the natural ability of macrophages to home to hypoxic areas 
to deliver the oncolytic virus to prostate tumours. The macrophages were co-
transduced with an adenovirus where the E1A gene, necessary for proliferation, 
is under the control of the PPT promoter (prostate-specific) and a construct 
containing the E1A/B gene under the control of a promoter containing HREs. 
Using this system, adenovirus replication will begin only when the transduced 
macrophages reach hypoxic regions. Orthotopic LNCaP tumours growing in 
mice showed regression and absence of metastasis following injections of 
transduced macrophages (Muthana et al. 2011). Advantages of this system are 
the low requirement of viral particles to induce a therapeutic effect and the 
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delay of the immune response to the recombinant virus due to the fact that the 
virus is in a latent state while in the macrophage and therefore antigen 
expression should be minimal. 
 
Although an exciting prospect, the use of oncolytic viruses and, the use of 
prostate-specific or cancer-specific regulatory regions to control the proliferation 
of the recombinant virus could yield other difficulties. Prostate-specific 
promoters are expressed in the majority of the cancer cells, since most of the 
prostate-specific promoters are active in more differentiated cells. However, 
prostate cancers do contain a small proportion of less differentiated cells in 
which these promoter would not be active, therefore selecting a population that 
is resistant to the new therapy. A possible solution for this problem is the 
combination of the oncolytic approach with suicide gene therapy. The use of a 
recombinant oncolytic vesicular stomatitis virus (VSV) encoding the cytosine 
deaminase/uracil phosphoribosyltransferase (CD::UPRT) suicide gene has 
proved to kill uninfected cells by means of the known bystander effect following 
prodrug treatment (Leveille et al. 2011). 
 
Another alternative is the use of oncolytic viruses with more conventional 
treatments such as chemotherapy. Using a Reovirus with oncolytic activity 
alongside docetaxel synergistic cytotoxic effects could be observed. 
Combinatorial treatment resulted in increased apoptotic/necrotic cell 
populations, reduced growth and increased survival in mice bearing PC3 
tumours in comparison to single treatments (Heinemann et al. 2011). Similar 
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results were obtained when using an oncolytic adenovirus and docetaxel in 
another prostate cancer xenograft model (Li et al. 2010). 
 
A noteworthy approach is the sensitization of tumour cells to cell 
death/apoptosis by inhibiting anti-apoptotic genes and introducing pro-apoptotic 
ones. Adenoviruses coding the REIC/Dkk-3 gene successfully induced cell 
death in PC3 prostate cancer cells. However, isolated resistant colonies 
showed overexpression of BiP/GRP78, an endoplasmic reticulum-residing 
chaperone protein. BiP/GRP78 siRNA knockdown rendered cells sensible to 
REIC/Dkk-3 triggered apoptosis, suggesting that BiP/GRP78 plays a key role in 
resistance to REIC/Dkk-3 mediated cell death (Tanimoto et al. 2010). 
The same principle has been used to induce cell death by infecting cells with an 
adenovirus encoding the mda-7/IL-24. The product of this gene is a member of 
the IL-10 cytokine family and is known for its anticancer activities. However, its 
activity is inhibited by the action of the myeloid cell leukemia-1 (Mcl-1) protein, 
therefore its down-regulation is a pre-requisite for inducing cell death using this 
system. Instead of knocking down Mcl-1, cells were treated with BI-97C1, an 
Apogossypol derivative, to induce Mcl-1 pharmacological inhibition. Infection of 
prostate cancer cells growing in nude mice with the adenovirus encoding the 
mda-7/IL24 combined with BI97C1 resulted in growth inhibition, increased 
apoptosis and decreased Ki-67 expression. Similar results were observed in Hi-
myc transgenic mice, which are prone to developing spontaneous prostate 
cancer (Dash et al. 2011). 
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In this work, the potential of a baculovirus system using a prostate-specific 
promoter and a GDEPT approach was evaluated for its use as a therapy for 
prostate cancer. It was confirmed that baculoviruses could deliver therapeutic 
genes not only into prostate cell lines but also prostate primary samples derived 
form patients. The NTR/CB1954 system also showed satisfactory results 
yielding high cell death in efficiently transduced prostate cells. While this work 
also uncovered a complex regulation governing hTGP expression, more 
research is needed to clarify the potential of this promoter region as a regulatory 
sequence driving the expression of the NTR enzyme. Genetic engineering to 
augment promoter strength while retaining tissue-specificity seems indeed 
necessary. Treatments that sensitize prostate cancer cells to NTR/CB1954 cell 
death or co-treatment with chemotherapy agents is also an exciting perspective. 
 
Another use for the hTGP promoter would be to enable it for an oncolytic 
approach. Since hTGP expression is highly prostate specific, it could be used to 
restrict the proliferation of viruses to prostate cells. However, as mentioned 
before, the oncolytic approach should also take into account the existence of 
non-permissive cell types and therefore this method should be combined with 
other form of therapy, preferentially, suicide gene therapy. 
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5.6 Conclusion  
This work has provided encouraging evidence supporting the use of baculovirus 
and suicide gene therapy as an alternative treatment for prostate cancer. The 
NTR/CB1954 system effectively killed prostate cancer cells. The baculovirus 
vector transduced not only prostate cancer cell lines but also prostate primary 
epithelial cell cultures. The dissection of the hTGP promoter revealed a layer of 
complexity regarding prostate specific-regulation. While many prostate-specific 
genes are mainly regulated by androgens through the AR, hTGP expression is 
regulated by an interaction between the AR and RARG. This new finding, will 
lead to a better understanding of how prostate-specific expression is achieved 
and will provide valuable information on the design and understanding of 
regulatory regions targeting prostate-specific expression. 
 	  	  	  	  	  	  	  	  	  	  	  	  
	   161	  
Appendices	  
A. Plasmid maps 
- pEGFP1 
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- CMV-NTR (F124K) 
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- pGL3-Basic 
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- pRL-CMV 
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- hTGP-NTR (EGFP1 backbone) 
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-pFASTBac1 
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B. Primers 
Primer name Sequence 5’- 3’ Purpose 
hTGP exon 1 for GAGATAGAGTCTTCCCTGGCA Amplify hTGP 
cDNA using 
RTPCR 
hTGp exon2 rev GGACTGCTCGTTTGGAACTCC Amplify hTGP 
cDNA using 
RTPCR 
GAPDH For AAGGTGAAGGTCGGAGTCAA Amplify GAPDH 
cDNA using 
RTPCR 
GAPDH Rev GGACACGGAAGGCCATGCCA Amplify GAPDH 
cDNA using 
RTPCR 
PSA fwd ATGTGGGTCCCGGTTGTCTT Amplify PSA cDNA 
using RT-PCR 
PSA rev TCAGGGGTTGGCCACGATGG Amplify PSA cDNA 
using RT-PCR 
PSAFor qPCR TGTGCTTCAAGGTATCACGTCAT Amplify PSA cDNA 
using qPCR 
PSARev qPCR TCAGGGGTTGGCCACGATGG Amplify PSA cDNA 
using qPCR 
5’ qHPRT GATGATGAACCAGGTTATGACC Amplify HPRT 
cDNA using qPCR 
3’ qHPRT CCAAATCCTCAGCATAATGATTAGG Amplify HPRT 
cDNA using qPCR 
hTGp mRNA A 
For 
GGGGGCTGCCAGAAGTATCAAA Amplify hTGP 
cDNA using qPCR 
hTGp mRNA A 
Rev 
CAGCACGGGGTCCCTCCTATC Amplify hTGP 
cDNA using qPCR 
RARG all-
transcripts 
For 
TGACCGGAACAAGAAGAAGAAAGAG Amplify RARG 
cDNA using qPCR 
RARG all-
transcripts 
Rev 
CTGGCAGAGCGAGGGGAAAGT Amplify RARG 
cDNA using qPCR 
RARB all-
transcripts 
For 
CCTGCCTTTGGAAATGGATGAC Amplify RARB 
cDNA using qPCR 
RARB all-
transcripts 
Rev 
TTGCTGGGTCGTCTTTTTCTGATA Amplify RARB 
cDNA using qPCR 
RARA all-
transcripts 
For 
GGCCCCCTCACCGACCTG Amplify RARA 
cDNA using qPCR 
RARA all-
transcripts 
Rev 
CGCTTCCGCACGTAGACCTTTAG Amplify RARA 
cDNA using qPCR 
AR1-2B 
qPCRFor 
CATCTTGTCGTCTTCGGAAATGTTA Amplify AR cDNA 
using qPCR 
AR1-
2BqPCRRev 
GAAGCCTCTCCTTCCTCCTGTAGTT Amplify AR cDNA 
using qPCR 
Region4hTGpFor ATGCAGTCTGTGGTATTTGTT ATGG Amplify upstream 
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region of the hTGP 
by qPCR 
Region4hTGpRe
v 
TTGGGTCTGGCTTCTTTCACTTAG Amplify upstream 
region of the hTGP 
by qPCR 
RegionAhTGpFor 
 
 
 
TTGTCTGTACTGCTTCCGTGTTCC Amplify region of 
the hTGP promoter 
by qPCR 
RegionAhTGpRe
v 
ATTTTCCCCCTGGTGTAGCATTAG Amplify region of 
the hTGP promoter 
by qPCR 
AB5’ CTGAAGTGCCAGGTTTGCTCCAT Amplify region of 
the hTGP promoter 
by qPCR 
AB3' AAAAGAATCCAATAAACCCCGAAGTC Amplify region of 
the hTGP promoter 
by qPCR 
RegionBhTGpFor ATTTACTAACTCCTCCCTGTCTCC Amplify region of 
the hTGP promoter 
by qPCR 
RegionBhTGpRe
v 
GCTGCTGTTCATGGTGCTAAG Amplify region of 
the hTGP promoter 
by qPCR 
RegionEhTGpFor CTTCCACCTGAGCACCCTGTCCT Amplify region of 
the hTGP promoter 
by qPCR 
RegionEhTGpRe
v 
GCAAGAAGAGCCTGAAAACCAC Amplify region of 
the hTGP promoter 
by qPCR 
RegionLhTGpFor AACTAAAACCCGGACCCTCTCA Amplify region of 
the hTGP promoter 
by qPCR 
RegionLhTGpRe
v 
GATGCTTGCTTTTCTCTGTATTTC Amplify region of 
the hTGP promoter 
by qPCR 
RegionMhTGpFo
r 
GTGCACTTCAGGGCTTGGTTTGT Amplify region of 
the hTGP promoter 
by qPCR 
RegionMhTGpRe
v 
AGTGAGGGGGCTGAATAATGATGC Amplify region of 
the hTGP promoter 
by qPCR 
RegionNhTGpFo
r 
ATCATTATTCAGCCCCCTCACTTT Amplify region of 
the hTGP promoter 
by qPCR 
RegionNhTGpRe
v 
AATTTTAATGGCTATCTGCTCTGC Amplify region of 
the hTGP promoter 
by qPCR 
NO5' CAACATTTCCACTTCAAGGCATTC Amplify region of 
the hTGP promoter 
by qPCR 
NO3' TACAATCAGTGTTGCAAAGAATAAGG
TT 
Amplify region of 
the hTGP promoter 
by qPCR 
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RegionOhTGpFo
r 
CACGCCTGGCAAGATGG Amplify region of 
the hTGP promoter 
by qPCR 
RegionOhTGpRe
v 
CACGCCTGGCAAGATGG Amplify region of 
the hTGP promoter 
by qPCR 
Region5hTGpFor TGCTTCTCAGTGCATACAACATCTC Amplify region of 
the hTGP promoter 
by qPCR 
Region5hTGpRe
v 
TAAGTCTAGGAACCCAGGCTAACC Amplify region of 
the hTGP promoter 
by qPCR 
Infusion hTGp 
4.5kb 5' region 
For 
TATCGATAGGTACCGAGCTCATTCCA
GAGCCATCCAGTTCCTTT 
Amplify 4.5 kb 
hTGP promoter 
Infusion hTGp 
3.5kb 5' region 
For 
TATCGATAGGTACCGAGCTCCCCCAC
AGGCACAGGCAT 
Amplify 3.5 kb 
hTGP promoter 
Infusion hTGp 
3kb 5' region For 
TATCGATAGGTACCGAGCTCGTGGG
GGAGGGGGATGCT 
Amplify 3 kb hTGP 
promoter 
Infusion hTGp 
2.5kb 5' region 
For 
TATCGATAGGTACCGAGCTCACCCAG
GATGTAGGCCCAGTTCT 
Amplify 2.5 kb 
hTGP promoter 
Infusion hTGp 
2kb 5' region For 
TATCGATAGGTACCGAGCTCCATCCC
TGGGCTTTTGGTCTG 
Amplify 2 kb hTGP 
promoter 
Infusion hTGp 
1.5kb 
5' region For 
TATCGATAGGTACCGAGCTCAATAGG
AACAGCTCCATCTTGCCA 
Amplify 1.5 kb 
hTGP promoter 
Infusion hTGp 
4.5kb 
3' region Rev 
GATCGCAGATCTCGAGAATGCCAGG
GAAGACTCTATCTCTGAT 
Amplify all deletion 
mutants 
NitroR ApaI For CCCTGGCATTCCGCGGGCCCAAGCT
TCCACCATGGATATCATTTCT  
Clone NTR into 
pGL3 basic 
plasmid instead of 
Luciferase 
NitroR NotI Rev TCTAGAGTCGCGGCCGCTCATTACAC
TTCGGTTAAGGTGATGTT  
Clone NTR into 
pGL3 basic 
plasmid instead of 
Luciferase 
XhoI-NTR For CTAGCCCGGGCTCGAGATGGATAT 
CATTTCTGTCGCCTTAAA 
Sequence 
nitroreductase 
XbaI-NTR Rev CCGCCCCGACTCTAGAATTACACTTC
GGTTAAGGTGATGTTTT 
Sequence 
Nitroreductase 
NTR seq For AGCGTCATTCCACTAAGGCATTTG pFastBac1 vector 
cloning site 
NTR seq Rev CGAGATTTCGGCAGCGTAGC  pFastBac1 vector 
cloning site 
pFastBac1F GCGTCACCCGGCAACCTT  
Amplify 
pFASTBac1 
plasmid 
pFastBac1R  GGGAACTGGGTGTAGCGTCG 
Amplify 
pFASTBac1 
plasmid 
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C. Antibodies 
 
Target Protein Manufacturer Isotype Application 
Androgen 
Receptor 
Santa Cruz 
Biotech SC-816 
Rabbit 
Pab 
WB, ChIP, IF 
RAR all isoforms Santa Cruz 
Biotech SC-773 
Rabbit 
Pab 
WB, ChIP 
RAR-Beta Santa Cruz 
Biotech SC-552 
Rabbit 
Pab 
WB 
RAR-Gamma Santa Cruz 
Biotech SC-550 
Rabbit 
Pab	   WB 
Tata binding 
protein 
Abcam 
Ab818 
Mouse 
Mab 
WB 
Beta-Actin Sigma 
A5316 
Mab WB 
Nitroreductase Prof Nicol Keith, 
University of 
Glasgow 
Mouse  
Mab 
WB 
Clusterin 
05-354 
Millipore Mouse 
Mab 
WB 
 
 
 
 
 
 
 
pUC/M13 
Forward 
CCCAGTCACGACGTTGTAAAACG 
Clone NTR into 
pGL3 basic 
plasmid instead of 
Luciferase 
pUC/M13 
Reverse AGCGGATAACAATTTCACACAGG 
Clone NTR into 
pGL3 basic 
plasmid instead of 
Luciferase 
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Abbreviations	  	  	  
5-FC= 5-fluorocytosine 
AAV= Adeno-associated virus 
Ad= Adenovirus 
AR= Androgen receptor 
ARE= Androgen responsive element 
atRA= all trans retinoic acid 
bp= base pairs 
BPH= Benign prostate hyperplasia 
BSA= Bovine serum albumin 
Bv= Bavulovirus 
CAR= Coxsackie/adenovirus receptor 
CB1954= 5-(Aziridin-1-yl)-2,4-dinitrobenzamide 
CD:UPRT= Cytosine deaminase/uracil phosphoribosiltransferase 
cDNA= complementary deoxyribonucleic acid 
ChIP= Chromatin immunoprecipitation 
CMV= Citomegalovirus 
CRPC= Castration-resistant prostate cancer 
CSC= Cancer stem cell 
CTK= Cytokeratin 
DHT= Dihydrotestosterone 
DMEM= Dulbecco’s modified Eagle’s medium 
DMSO= Dimethyl sulfoxide 
DNA= Deoxyribonucleic acid 
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dNTP= Deoxyribonucleotide triphosphate 
dsDNA= Double stranded deoxyribonucleic acid 
E= early 
EDTA= Ethylenediaminetetraacetic acid 
EGF= Epidermal growth factor 
EGFP= Enhanced green fluorescent protein 
ER= Oestrogen receptor 
ERE= Oestrogen responsive element 
FACS= Fluorescent activated cell sorting 
FCS= Foetal calf serum 
FITC= Fluorescein isothiocyanate 
GAPDH= Glyceraldehyde 3-phosphate dehydrogenase 
GCV= Gancyclovir 
GDEPT= Gene-directed enzyme prodrug therapy 
HAT= Histone acetyltransferase  
HDAC= Histone deacetylase 
hKLK2= Human kallikrein 2 
HRE= Hypoxia responsive element 
HRP= Horseradish peroxidase 
HSP= Heat shock protein 
HSV= Herpes simplex virus 
HSVTK= Herpes simplex virus thymidine kinase 
hTERT= Human telomerase reverse transcriptase 
hTGP= Human prostate-specific transglutaminase 
HVEM= Herpes virus entry mediator 
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IE= Immediate early 
IgG= Immunoglobulin G 
IL= Interleukin 
IPTG= Isopropil-β-D-1-thiogalactopyranoside 
IR/DR= Indirect repeat/direct repeat 
ITR= Inverted terminal repeats 
ITS-G= Insulin-transferrin-selenium 
kb= kilobase 
KSFM= Keratinocyte serum-free media 
L= Late 
LB= Luria Broth 
mM= Milimolar 
MOI= Multiplicity of infection 
MoMuLV= Moloney murine leukemia virus 
mRNA= Messenger ribonucleic acid 
MTS= (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl-
2H-tetrazolium) 
NLS= Nuclear localization signal 
nM= Nanomolar 
nm= Nanometer 
NSC= Neural stem cell 
NTR= Nitroreductase 
PAGE= Polyacrylamide gel electrophoresis 
PBS= Phosphate buffered saline 
PCR= Polymerase chain reaction 
	   174	  
PDK= Phosphoinositide dependent kinase 
PEG= Polyethylene glycol 
pfu= Plaque forming unit 
PhIP= 2-amino-1methyl-6phenylimidazo[4,5-b]pyridine 
PIA= Proliferative inflammatory atrophy 
PIN= Prostate intraepithelial neoplasia 
PIP3= Phosphatidylinositol-(3,4,5)-triphosphate 
PPAR= Peroxisome proliferator-activated receptor 
PSA= Prostate specific antigen 
PSMA= Prostate specific membrane antigen 
PTEN= Phosphatase and tensin homologue 
qPCR= Quantitative polymerase chain reaction 
R1881= Methyltrienolone 
RA= Retinoic acid  
RAR= Retinoic acid receptor 
RARE= Retinoic acid responsive element 
Rb= Retinoblastoma 
RNA= Ribonucleic acid 
ROS= Reactive oxygen species 
RPM= Revolutions per minute 
RPMI= Roswell Park Memorial Institute 
rRNA= Ribosomal ribonucleic acid 
RT= Room temperature 
RT-PCR= Reverse transcription polymerase chain reaction 
SB= Sleeping beauty 
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SDS= Sodium dodecyl sulfate 
siRNA= Small interfering ribonucleic acid 
SOC= Super Optimal broth with Catabolic repressor 
STAT= Signal transducer and activator of transcription 
TBP= TATA binding protein 
TBS= Tris-buffered saline 
tRNA= Transfer ribonucleic acid 
TTNPB= (E)-4-[2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthylenyl-1-propenyl] 
benzoic acid 
U= Unit 
UGM= Urogenital sinus 
UGS= Urogenital mesenchyme 
v/v= Volume/volume 
VEGF= Vascular endothelial growth factor 
VSV= Vesicular stomatitis virus 
w/v= Weight/volume 
WT= Wild-type 
X-Gal= 5-bromo-4chloro-3-indolyl-beta-D-galacto-pyranoside 
µM= Micromolar 
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